NZ623456B2 - Genetically modified major histocompatibility complex mice - Google Patents
Genetically modified major histocompatibility complex mice Download PDFInfo
- Publication number
- NZ623456B2 NZ623456B2 NZ623456A NZ62345612A NZ623456B2 NZ 623456 B2 NZ623456 B2 NZ 623456B2 NZ 623456 A NZ623456 A NZ 623456A NZ 62345612 A NZ62345612 A NZ 62345612A NZ 623456 B2 NZ623456 B2 NZ 623456B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- human
- mouse
- mhc
- polypeptide
- microglobulin
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title claims abstract description 378
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title claims abstract description 372
- 241000699670 Mus sp. Species 0.000 title description 64
- 241000282414 Homo sapiens Species 0.000 claims abstract description 857
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 376
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 337
- 229920001184 polypeptide Polymers 0.000 claims abstract description 321
- 239000002773 nucleotide Substances 0.000 claims abstract description 185
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 185
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 301
- 108090000623 proteins and genes Proteins 0.000 claims description 171
- 241000283984 Rodentia Species 0.000 claims description 94
- 241001465754 Metazoa Species 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 67
- 230000014509 gene expression Effects 0.000 claims description 51
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 44
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 44
- 108700043516 mouse H-2Kb Proteins 0.000 claims description 36
- 230000001086 cytosolic effect Effects 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 108700024394 Exon Proteins 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 210000001161 mammalian embryo Anatomy 0.000 claims description 20
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 11
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 11
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 10
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 206
- 210000001744 T-lymphocyte Anatomy 0.000 description 70
- 239000000427 antigen Substances 0.000 description 70
- 108091007433 antigens Proteins 0.000 description 70
- 102000036639 antigens Human genes 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 68
- 102000004169 proteins and genes Human genes 0.000 description 68
- 241000700159 Rattus Species 0.000 description 64
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 59
- 108091008874 T cell receptors Proteins 0.000 description 35
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 35
- 108091054437 MHC class I family Proteins 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 22
- 210000000822 natural killer cell Anatomy 0.000 description 22
- 239000012634 fragment Substances 0.000 description 21
- 238000006467 substitution reaction Methods 0.000 description 20
- 102000043129 MHC class I family Human genes 0.000 description 19
- 210000000612 antigen-presenting cell Anatomy 0.000 description 19
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 18
- 108700028369 Alleles Proteins 0.000 description 17
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 17
- 230000008685 targeting Effects 0.000 description 17
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 16
- 230000028993 immune response Effects 0.000 description 16
- 101100042648 Drosophila melanogaster sing gene Proteins 0.000 description 14
- 101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000005260 human cell Anatomy 0.000 description 11
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 10
- 101000986079 Homo sapiens HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102000007079 Peptide Fragments Human genes 0.000 description 8
- 108010033276 Peptide Fragments Proteins 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 210000005220 cytoplasmic tail Anatomy 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 238000011714 129 mouse Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000699729 Muridae Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 3
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 244000052637 human pathogen Species 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101150118346 HLA-A gene Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 101150017040 I gene Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 241000121210 Sigmodontinae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Chemical group OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- 101710097567 12 kDa protein Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000699725 Acomys Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 241000398949 Calomyscidae Species 0.000 description 1
- 241000700193 Calomyscus Species 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241001095404 Dipodoidea Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100028966 HLA class I histocompatibility antigen, alpha chain F Human genes 0.000 description 1
- 102210042925 HLA-A*02:01 Human genes 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000986087 Homo sapiens HLA class I histocompatibility antigen, B alpha chain Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000986080 Homo sapiens HLA class I histocompatibility antigen, alpha chain F Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001046461 Lophiomys imhausi Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000398750 Muroidea Species 0.000 description 1
- 101000924587 Mus musculus Adenomatous polyposis coli protein Proteins 0.000 description 1
- 241000699669 Mus saxicola Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091008877 NK cell receptors Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 241000398990 Nesomyidae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 208000034615 apoptosis-related disease Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000048974 human HLA-B Human genes 0.000 description 1
- 230000009403 human autoimmunity Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Disclosed is a non-human animal comprising at an endogenous Major Histocompatibility Complex I (MHC I) locus a nucleotide sequence encoding a chimeric human/non-human MHC I polypeptide, wherein a human portion of the chimeric polypeptide comprises ?1, ?2, and ?3 domains of a human MHC I polypeptide, and wherein the non-human animal expresses the chimeric human/non-human MHC I polypeptide. and wherein the non-human animal expresses the chimeric human/non-human MHC I polypeptide.
Description
GENETlCALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit of priority to US. Provisional Patent ation
Nos. 61/552,582 and 61/552,587, both filed October 28, 2011, and US. Provisional Patent
ation No. 61/700,908, filed September 14, 2012, all of which are hereby incorporated
by reference herein in their entireties.
FIELD OF THE INVENTION
Present invention relates to a genetically modified non—human animal, e.g., a
rodent (e.g., a mouse or a rat), that expresses a human or humanized Major
ompatibility Complex (MHC) class I molecule. The invention also relates to a
genetically modified non-human animal, e.g., a mouse or a rat, that expresses a human or
humanized MHC l protein (e.g., MHC l a chain) and/or a human or humanized [32
microglobulin; as well as embryos, tissues, and cells expressing the same. The invention
further provides methods for making a genetically modified non-human animal that
expresses human or humanized MHC class I protein (e.g., MHC l a chain) and/or [32
lobulin. Also provided are s for identifying and evaluating peptides in the
context of a humanized ar immune system in vitro or in a genetically modified non-
human animal, and s of modifying an MHC l and/or a [32 microglobulin locus of a
non-human animal, e.g., a mouse or a rat, to s a human or humanized MHC l and/or
[32 microglobulin.
BACKGROUND OF THE lNVENTION
in the adaptive immune response, foreign antigens are recognized by receptor
molecules on B lymphocytes (e.g., immunoglobulins) and T lymphocytes (e.g., T cell
receptor or TCR). These foreign antigens are presented on the surface of cells as peptide
fragments by specialized proteins, cally referred to as major histocompatibility
complex (MHC) molecules. MHC molecules are encoded by multiple loci that are found as a
linked cluster of genes that spans about 4 Mb. ln mice, the MHC genes are found on
chromosome 17, and for historical s are referred to as the histocompatibility 2 (H-2)
genes. in humans, the genes are found on chromosome 6 and are called human leukocyte
antigen (HLA) genes. The loci in mice and humans are polygenic; they include three highly
polymorphic classes of MHC genes (class I, ll and Ill) that exhibit similar organization in
human and murine genomes (see and respectively).
MHC loci exhibit the t polymorphism in the genome; some genes are
represented by >300 alleles (e.g., human HLA—DRfi and human HLA-B). All class l and II
MHC genes can present peptide fragments, but each gene expresses a n with different
binding characteristics, reflecting polymorphisms and allelic variants. Any given individual
has a unique range of peptide fragments that can be ted on the cell surface to B and
T cells in the course of an immune response.
Both humans and mice have class i MHC genes (see HS. 2 and . In
humans, the cal class l genes are termed HLA-A, HLA-B and HLA—C, whereas in mice
they are H-2K, H-ZD and H—2L. Class I molecules t of two chains: a polymorphic 0c—
chain (sometimes referred to as heavy chain) and a smaller chain called BZ-microglobulin
(also known as light chain), which is generally not polymorphic (HQ 1). These two chains
form a valent heterodimer on the cell surface. The a-chain contains three s
(a1, a2 and 0L3). Exon 1 of the a-chain gene encodes the leader sequence, exons 2 and 3
encode the (11 and a2 s, exon 4 encodes the 0:3 domain, exon 5 encodes the
transmembrane domain, and exons 6 and 7 encode the cytoplasmic tail. The a-chain forms
a peptide-binding cleft involving the (x1 and a2 domains (which resemble lg-like domains)
followed by the 0:3 , which is similar to BZ-microglobulin.
(52 microglobulin is a non-glycosyiated 12 kDa protein; one of its functions is to
stabilize the MHC class l a~chain. Unlike the n, the [32 microglobulin does not span
the membrane. The human (32 microglobulin locus is on chromosome 15, while the mouse
locus is on chromosome 2. [32 microglobulin gene consists of 4 exons and 3 introns.
Circulating forms of [32 microglobulin are present in the serum, urine, and other body fluids;
thus, the non-covalently MHC l—associated (32 microglobulin can be exchanged with
ating [32 microglobulin under physiological conditions.
Class I MHC molecules are expressed on all nucleated cells, including tumor
cells. They are expressed specifically on T and B lymphocytes, macrophages, dendritic cells
and neutrophils, among other cells, and on to y peptide nts (typically 8-10
amino acids in length) on the surface to CD8+ cytotoxic T lymphocytes (CTLs). CTLs are
specialized to kill any cell that bears an MHC I-bound peptide recognized by its own
membrane-bound TCR. When a cell displays peptides derived from ar proteins not
normally present (e.g., of viral, tumor, or other non-self origin), such peptides are recognized
by CTLs, which become activated and kill the cell displaying the peptide.
Typically, presentation of normal (i.e., self) proteins in the context of MHC
molecules does not elicit CTL activation due to the tolerance mechanisms. However, in some
diseases (e.g., cancer, mune diseases) peptides derived from self-proteins become a
target of the cellular component of the immune , which results in destruction of cells
presenting such peptides. Although there has been advancement in recognizing some selfderived
antigens that elicit cellular immune response (e.g., ns associated with various
cancers), in order to e identification of peptides recognized by human CTLs through
MHC class I molecules there remains a need for both in vivo and in vitro systems that mimic
s of the human cellular immune system. Systems that mimic the human cellular
immune system can be used in identifying disease-associated antigens in order to develop
human therapeutics, e.g., vaccines and other biologics. s for assessing antigen
recognition in the t of the human immune system can assist in identifying
therapeutically useful CTL populations (e.g., useful for studying and combatting human
disease). Such systems can also assist in enhancing the activity of human CTL populations
to more effectively combat infections and foreign antigen-bearing entities. Thus, there is a
need for biological systems (e.g., genetically engineered animals) that can generate an
immune system that displays components that mimic the function of human immune .
SUMMARY OF THE INVENTION
[0008a] In one aspect, the present ion provides a non-human animal comprising
at an endogenous Major Histocompatibility Complex I (MHC I) locus a nucleotide ce
encoding a chimeric human/non-human MHC I polypeptide,
wherein a human portion of the chimeric polypeptide comprises α1, α2, and α3
domains of a human MHC I polypeptide, and
wherein the non-human animal expresses the chimeric human/non-human MHC I
polypeptide.
] In a r aspect, the present invention provides a method of modifying an
MHC I locus of a mouse to s a chimeric human/mouse MHC I polypeptide, wherein the
method comprises replacing at the endogenous MHC I locus a nucleotide sequence encoding
α1, α2, and α3 domains of a mouse MHC I polypeptide with a nucleotide sequence encoding
α1, α2, and α3 domains of a human MHC I polypeptide.
A biological system for generating or identifying peptides that associate with
human MHC class I proteins and chimeras thereof, and bind to CD8+ T cells, is ed.
Non-human animals comprising non-human cells that express human or humanized
molecules that function in the cellular immune response are provided. Humanized rodent loci
that encode human or human or humanized MHC I and β2 microglobulin proteins are also
provided. Humanized rodent cells that express human or humanized MHC and 12
lobulin molecules are also provided. In vivo and in vitro systems are provided that
comprise humanized rodent cells, wherein the rodent cells express one or more human or
zed immune system molecules.
Provided herein is a non-human animal, e.g., a rodent (e.g., a mouse or a rat),
comprising in its genome a nucleotide sequence ng a chimeric human/non-human
(e.g., human/rodent, e.g., human/mouse or human/rat) MHC l polypeptide, wherein a human
portion of the chimeric polypeptide comprises an extracellular domain of a human MHC l
polypeptide. Specifically, provided herein is a non-human animal comprising at an
endogenous MHC l locus a nucleotide sequence encoding a chimeric non-human
MHC l polypeptide, wherein a human portion of the chimeric polypeptide ses an
extracellular domain of a human MHC l polypeptide, and wherein the animal expresses the
chimeric human/non-human MHC | polypeptide. in one aspect, the animal does not express
an extracellular domain of an endogenous non-human MHC l polypeptide from an
endogenous non-human MHC l locus. ln one aspect of the invention, the non-human animal
(e.g., a , e.g., a mouse or a rat) ses two copies of the MHC | locus comprising a
nucleotide sequence encoding chimeric human/non—human (e.g., human/rodent, e.g.,
human/mouse or human/rat) MHC l polypeptide. ln another aspect of the ion, the
animal comprises one copy of the MHC l locus comprising a nucleotide sequence encoding
a chimeric human/non-human MHC l polypeptide. Thus, the animal may be homozygous or
heterozygous for the MHC l locus comprising a nucleotide sequence encoding chimeric
human/non-human MHC l polypeptide. in various ments, the nucleotide ce
encoding a chimeric human/non-human MHC l polypeptide is comprised in the germline of
the non—human animal (e.g., rodent, e.g., rat or mouse).
In one aspect, the nucleotide sequence encoding the ic human/non—human
MHC l is operably linked to endogenous non—human regulatory ts, e.g., promoter,
enhancer, silencer, etc. in one embodiment, a human portion of the chimeric polypeptide
comprises a human leader sequence. In an additional embodiment, the human n of
the chimeric polypeptide comprises a1, a2, and a3 domains of the human MHC l
polypeptide. The human MHC l polypeptide may be selected from a group consisting of
HLA-A, HLA-B, and HLA-C. in one embodiment, the human MHC l polypeptide is an HLA-
A2 ptide, e.g., an HLA—A2.1 polypeptide.
In one aspect, the genetically engineered non-human animal is a rodent. in one
embodiment, the rodent is a mouse. Thus, in one embodiment, the endogenous man
locus is a mouse locus, e.g., a mouse H—2K, H-2D or H-2L locus. in one embodiment, the
non-human portion of the chimeric human/non-human MHC l polypeptide comprises
transmembrane and cytoplasmic domains of the endogenous non-human MHC l
polypeptide. Thus, in an embodiment wherein the non-human animal is a mouse, the
nous non-human MHC l locus may be an H-2K locus (e.g., H—2Kb locus) and the
endogenous non—human MHC l polypeptide may be an H-2K polypeptide; therefore, the
chimeric human/non—human MHC l ptide may comprise transmembrane and
cytoplasmic domains of H-2K polypeptide. in another embodiment wherein the non-human
animal is a mouse, the endogenous non—human MHC l locus may be an H-2D locus and the
endogenous non-human MHC l polypeptide may be an H—ZD polypeptide; therefore, the
chimeric human/non-human MHC l polypeptide may comprise transmembrane and
cytoplasmic domains of H-2D polypeptide. Similarly, in another embodiment, the
nous non-MHC l locus may be an H-2L locus and the endogenous non—human MHC
l ptide may be an H—2L polypeptide; therefore, the chimeric human/non-human MHC l
polypeptide may comprise transmembrane and cytoplasmic domains of H-2L polypeptide.
Also provided herein is a mouse comprising at an nous H—2K locus a
nucleotide sequence encoding a chimeric human/mouse MHC l polypeptide, wherein a
human portion of the chimeric polypeptide comprises an extracellular domain of a human
HLA-A (e.g., ) ptide and a mouse portion comprises transmembrane and
asmic domains of a mouse H-2K polypeptide, and wherein the mouse expresses the
chimeric human/mouse MHC l polypeptide. in some embodiments, the mouse does not
express an extracellular domain of the mouse H-2K polypeptide from an endogenous H—2K
locus. in one aspect, the tide sequence encoding a chimeric human/mouse MHC |
polypeptide is operably linked to endogenous mouse regulatory elements. The human
portion of the chimeric polypeptide may se a human leader sequence. it may also
comprise a1, a2, and a3 domains of the human MHC l ptide. The human MHC l
polypeptide may be HLA-A polypeptide, e.g., HLA—A2.1 polypeptide. in one aspect, the
mouse H-2K locus is an H-2Kb locus.
Another aspect of the invention relates to a non-human animal, e.g., a rodent
(e.g., a mouse or a rat), comprising in its genome a nucleotide sequence encoding a human
or humanized {52 microglobulin polypeptide. Thus, ed herein is a non-human animal
sing at an endogenous non-human [32 microglobulin locus a nucleotide sequence
encoding a human or humanized {32 microglobulin polypeptide, wherein the animal
expresses the human or humanized [32 lobulin polypeptide. in one aspect, the animal
does not s a functional endogenous non-human {52 microglobulin polypeptide from an
endogenous non-human [32 microglobulin locus. in one aspect, the animal comprises two
copies of the [32 microglobulin locus encoding the human or humanized [32 microglobulin
polypeptide; in another ment, the animal comprises one copy of the [32 microglobulin
locus encoding the human or humanized [32 microglobulin polypeptide. Thus, the animal
may be homozygous or zygous for the [32 microglobulin locus encoding the human or
humanized 62 microglobulin polypeptide. In various embodiments, the nucleotide sequence
encoding the human or humanized [32 microglobulin polypeptide is comprised in the
germline of the non-human animal (e.g., rodent, e.g., rat or mouse). In one embodiment, a
nucleotide sequence ng a human or humanized [32 microglobulin polypeptide
comprises a nucleotide sequence encoding a polypeptide comprising a human [32
microglobuiin amino acid sequence. In one embodiment, the ptide is capable of
binding to an MHC I protein.
In some embodiments, the nucleotide ce encoding the human or
humanized $2 microglobulin polypeptide is operably linked to endogenous non-human [32
microglobuiin regulatory ts. In one aspect, the nucleotide sequence encoding the
human or humanized [32 microglobulin ponpeptide comprises a nucleotide sequence set
forth in exon 2 to exon 4 of a human [32 microglobuiin gene. In another aspect, the
nucleotide sequence encoding the human or humanized [52 microglobulin polypeptide
comprises nucleotide sequences set forth in exons 2, 3, and 4 of a human [32 microglobulin
gene. In a further aspect, the nucleotide sequence also comprises a nucleotide sequence
set forth in exon 1 of a non—human [32 microglobulin gene. In some embodiments, the non—
human animai is a rodent (e.g., mouse or a rat); thus, the non—human B2 IobuIin locus
is a rodent (e.g., a mouse or a rat) [32 microglobulin locus.
Also provided is a mouse comprising at an endogenous [32 microglobulin Iocus a
nucleotide sequence encoding a human or humanized [32 lobulin polypeptide,
wherein the mouse expresses the human or humanized [32 microglobulin polypeptide. In
some embodiments, the mouse does not express a onal endogenous mouse [32
microglobulin from an endogenous [32 microglobulin locus. The tide ce may
be linked to endogenous mouse reguIatory elements. In one aspect, the nucleotide
sequence comprises a nucleotide sequence set forth in exon 2 to exon 4 of a human [32
microglobulin gene. Alternatively, the nucleotide sequence encoding the human or
humanized [32 microglobulin polypeptide may comprise tide ces set forth in
exons 2, 3, and 4 of a human [32 microglobulin gene. The nucleotide sequence encoding
the human or humanized [32 microglobuiin polypeptide may further comprise a nucleotide
sequence of exon 1 of a mouse [32 microglobuiin gene. In one ment, a nucIeotide
sequence encoding a human or zed [32 microglobulin polypeptide comprises a
nucleotide sequence encoding a poiypeptide comprising a human [32 microglobulin amino
acid sequence. In one embodiment, the ptide is capable of binding to an MHC I
protein.
2012/062042
The invention further provides a non—human animal (e.g., a , e.g., a mouse
or a rat) comprising in its genome a nucleotide sequence encoding a chimeric human/non-
human MHC l polypeptide and a nucleotide sequence encoding a human or humanized {32
microglobulin polypeptide. In one embodiment, the invention provides a man animal
comprising in its genome a first nucleotide sequence encoding a chimeric human/non-
human MHC l polypeptide, wherein a human portion of the chimeric polypeptide comprises
an extracellular domain of a human MHC l polypeptide; and a second nucleotide sequence
encoding a human or humanized [52 microglobulin polypeptide, wherein the first nucleotide
ce is located at an endogenous non-human MHC l locus, and the second nucleotide
sequence is located at an endogenous non-human {32 microglobulin locus, and wherein the
animal expresses the chimeric human/non-human MHC l polypeptide and the human or
humanized [32 microglobulin polypeptide. in one aspect, the animal is a mouse. Thus, the
endogenous MHC | locus may be selected from a group consisting of H-2K, H-2D, and H—2L
locus. In one embodiment, the endogenous mouse locus is an H-2K locus (e.g., H—2Kb
locus). In one embodiment, the human MHC l polypeptide is selected from the group
ting of HLA—A, HLA—B, and HLA—C polypeptide. in one aspect, the human MHC l
polypeptide is HLA—A, e.g., HLA-A2 (e.g., HLA-A2.1). ln s embodiments, the first and
the second nucleotide sequences are comprised in the germline of the non-human animal
(e.g., , e.g., mouse or rat).
Therefore, the invention provides a mouse comprising in its genome a first
nucleotide sequence encoding a chimeric human/mouse MHC l polypeptide, wherein a
human portion of the chimeric polypeptide comprises an extracellular domain of a human
HLA—A (e.g., ) and a mouse portion comprises transmembrane and cytoplasmic
domains of a mouse H-ZK; and a second tide sequence encoding a human or
humanized [32 microglobulin polypeptide, wherein the first tide ce is located at
an nous H-2K locus and the second nucleotide sequence is located at an
endogenous mouse [32 microglobulin locus, and wherein the mouse ses the chimeric
human/mouse MHC l polypeptide and the human or humanized [32 microglobulin
polypeptide. In one embodiment, the non-human animal (e.g., the mouse) comprising both
the chimeric MHC l polypeptide and human or humanized [32 lobulin polypeptide does
not express an ellular domain of an endogenous man MHC l polypeptide (e.g.,
the mouse H-ZK polypeptide) and/or a functional endogenous non-human (e.g., the mouse)
[32 microglobulin polypeptides from their respective endogenous loci. in one aspect, the
animal (e.g., the mouse) comprises two copies of each of the first and the second nucleotide
sequence. In another aspect, the animal (e.g., the mouse) comprises one copy of the first
WO 63346
and one copy of the second nucleotide sequences. Thus, the animal may be homozygous
or heterozygous for both the first and the second nucleotide sequences.
in one aspect, the first tide sequence is operably linked to endogenous
non-human (e.g., mouse) MHC l tory elements, and the second nucleotide sequence
is ly linked to endogenous non-human (e.g., mouse) [32 microglobulin elements. The
human portion of the chimeric polypeptide may comprise a1, a2 and (13 domains of the
human MHC l polypeptide. The second nucleotide sequence may comprise a tide
sequence set forth in exon 2 to exon 4 of a human [32 microglobulin gene. Alternatively, the
second nucleotide sequence may comprise nucleotide sequences set forth in exons 2, 3,
and 4 of a human [32 microglobulin gene. In one aspect, the mouse comprising both the
chimeric MHC l polypeptide and human or humanized [52 microglobulin polypeptide may be
such that the expression of human or humanized (32 microglobulin increases the expression
of the chimeric human/mouse MHC l polypeptide as compared to the sion of the
ic human/mouse MHC l polypeptide in the absence of expression of human or
humanized [32 microglobulin polypeptide.
Also provided are methods of making genetically engineered non-human animals
(e.g., rodents, e.g., mice or rats) described herein. Thus, in one embodiment, provided is a
method of modifying an MHC l locus of a rodent (e.g., a mouse or a rat) to s a
chimeric human/rodent (e.g., mouse or human/rat) MHC l polypeptide, wherein the
method comprises replacing at the endogenous MHC l locus a nucleotide sequence
encoding an extracellular domain of a rodent MHC l polypeptide with a nucleotide sequence
encoding an extracellular domain of a human MHC l ptide. In another embodiment,
provided is a method of modifying a {32 microglobulin locus of a rodent (e.g., a mouse or a
rat) to express a human or humanized [32 microglobulin polypeptide, wherein the method
comprises replacing at the endogenous rodent (e.g., mouse or rat) {32 microglobulin locus a
nucleotide ce encoding a rodent (e.g., a mouse or a rat) [32 microglobulin polypeptide
with a nucleotide sequence encoding a human or humanized [32 microglobulin ptide.
in such methods, the replacement may be made in a single ES cell, and the single ES cell
may be introduced into a rodent (e.g., a mouse or a rat) to make an embryo. The resultant
rodent (e.g., a mouse or a rat) can be bred to generate a double humanized animal.
Thus, the invention also provides a method of making double humanized
animals, e.g., rodents (e.g., mice or rats). in one embodiment, ed is a method of
making a genetically modified mouse comprising (a) modifying an MHC l locus of a first
mouse to s a chimeric mouse MHC | polypeptide comprising replacing at the
endogenous mouse MHC l locus a nucleotide sequence encoding an extracellular domain of
a mouse MHC l polypeptide with a nucleotide sequence encoding an ellular domain of
a human MHC l polypeptide, (b) modifying a 62 microglobulin locus of a second mouse to
s a human or humanized B2 microglobulin polypeptide comprising replacing at the
endogenous mouse {32 microglobulin locus a nucleotide sequence encoding a mouse {52
microgiobulin polypeptide with a nucleotide sequence encoding a human or humanized {32
microgiobulin polypeptide; and (c) breeding the first and the second mouse to generate a
genetically modified mouse comprising in its genome a first nucleotide sequence ng a
chimeric human/mouse MHC i ptide and a second nucleotide sequence encoding a
human or humanized [32 microglobuiin polypeptide, wherein the genetically modified mouse
expresses the chimeric human/mouse MHC l polypeptide and the human or humanized [32
microglobulin polypeptide. in some ments, the MHC | locus is selected from H-2K,
H—2D, and H-2L; in some embodiments, the human MHC l polypeptide is selected from HLA-
A, HLA-B, and HLA-C. in one embodiment, the MHC l locus is an H-2K locus, the human
MHC l polypeptide is HLA—A (e.g., HLA-A2), and the mouse expresses a ic H-
2K polypeptide (e.g., HLA—AZ/H-ZK polypeptide). in one , the chimeric HLA-A2/H-2K
polypeptide comprises an extracellular domain of the HLA-A2 polypeptide and cytoplasmic
and transmembrane domains of H-2K polypeptide. in one aspect, the second nucleotide
sequence comprises tide sequences set forth in exons 2, 3, and 4 (e.g., exon 2 to
exon 4) of a human [32 microglobulin gene, and a nucleotide sequence set forth in exon 1 of
a mouse {32 lobulin gene.
Also provided herein are cells, e.g., isolated antigen-presenting cells, derived
from the non—human animals (e.g., rodents, e.g., mice or rats) described herein. Tissues
and embryos derived from the non—human animals bed herein are also provided.
in yet another embodiment, the invention provides methods for identification of
antigens or antigen epitopes that elicit immune response, methods for evaluating a vaccine
ate, s for identification of high affinity T cells to human pathogens or cancer
antigens.
Any of the embodiments and aspects described herein can be used in
conjunction with one another, unless otherwise indicated or apparent from the context.
Other embodiments will become apparent to those skilled in the art from a review of the
ensuing detailed description. The following ed description includes ary
representations of various embodiments of the ion, which are not restrictive of the
invention as claimed. The accompanying figures constitute a part of this specification and,
together with the description, serve only to illustrate embodiments and not to limit the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
is a schematic g of the four domains of a class I MHC le: oc—
chain ning the a1, a2 and (x3 domains and the non-covalently associated fourth
domain, BZ—microglobulin ((32m). The gray circle represents a peptide bound in the e—
binding cleft.
is a schematic representation (not to scale) of the relative genomic
structure of the human HLA, showing class I, II and Ill genes.
is a schematic representation (not to scale) of the ve genomic
structure of the mouse MHC, showing class I, II and III genes.
illustrates a viral vector construct containing a cDNA encoding a chimeric
HLA-A/H—2K polypeptide with an IRES—GFP reporter (A); and histograms comparing
expression of human HLA—A2 in MG87 cells transduced with HLA—A2 (dashed line), HLA-
A2/H-2K (dotted line), or no transduction (solid line) either alone (left) or co-transduced with
zed [32 microglobulin (right) (B). Data from horizontal gates presented graphically in
(B) is illustrated as percent of cells expressing the construct in the table in (C).
is a schematic diagram (not to scale) of the targeting strategy used for
making a ic H-2K locus that expresses an extracellular region of a human HLA-A2
protein. Mouse sequences are represented in black and human sequences are represented
in white. L=leader, UTR=untranslated region; TM=transmembrane domain,
CYT=cytoplasmic domain, HYG=hygromycin.
demonstrates expression (% total cells) of HLA—A2 (left) and H-2K (right)
in cells isolated from either a wild-type (WT) mouse or a heterozygous mouse carrying the
chimeric HLA-A2/H—2K locus (HLA-A/H-ZK HET).
FIG. BB is a dot plot of in vivo expression of the chimeric HLA-A2/H-2K protein in
a heterozygous mouse harboring a chimeric HLA-A2/H-2K locus.
shows a ing strategy (not to scale) for humanization of a [32
lobulin gene at a mouse (32 microglobulin locus. Mouse sequences are in black and
human sequences are in white. NEO=neomycin.
shows a entative dot plot of HLA class I and human [32
microglobulin expression on cells isolated from the blood of wild-type (WT) mice, mice
heterozygous for chimeric /H-2K, and mice heterozygous for chimeric HLA—A2/H-2K
and heterozygous for humanized (32 microglobulin e heterozygous; class l/[32m HET).
shows a representative histogram of human HLA class I expression (X
axis) on cells isolated from the blood of wild-type (WT), chimeric HLA-A2/H—2K heterozygous
(cIass I HET), and ic HLA-A2/H2K/humanized {32 microglobulin double heterozygous
(cIass I/ [32m HET) mice.
shows the results of IFNy EIispot assays for human T celIs exposed to
antigen-presenting cells (APCs) from wiId—type mice (WT APCs) or mice heterozygous for
both chimeric HLA-A2/H-2K and zed BZ microglobuIin (doubIe HET APCs) in the
presence of flu (left) or EBV (right) peptides. StatisticaI analysis was performed using one
way ANOVA with a Tukey’s Multiple Comparison Post Test.
ED DESCRIPTION OF THE INVENTION
Definitions
The present invention provides cally ed non—human animals (e.g.,
mice, rats, rabbits, etc.) that express human or humanized MHC I and/or :32 microglobulin
polypeptides; embryos, cells, and tissues comprising the same; methods of making the
same; as well as methods of using the same. Unless defined otherwise, all terms and
phrases used herein include the meanings that the terms and s have attained in the
art, unless the contrary is clearly indicated or cIearIy apparent from the context in which the
term or phrase is used.
The term "conservative,” when used to describe a conservative amino acid
substitution, includes substitution of an amino acid residue by another amino acid residue
having a side chain R group with similar chemical properties (e.g., charge or hydrophobicity).
Conservative amino acid substitutions may be achieved by modifying a nucleotide sequence
so as to introduce a nucleotide change that will encode the conservative substitution. In
general, a conservative amino acid tution will not substantially change the functional
properties of interest of a protein, for example, the y of MHC I to present a e of
interest. Examples of groups of amino acids that have side chains with similar chemicaI
properties include aliphatic side chains such as glycine, alanine, , Ieucine, and
isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide-containing
side chains such as asparagine and glutamine; aromatic side chains such as phenylalanine,
tyrosine, and tryptophan; basic side chains such as lysine, arginine, and histidine; acidic side
chains such as aspartic acid and glutamic acid; and, sulfur-containing side chains such as
cysteine and methionine. Conservative amino acids substitution groups e, for example,
vaIine/Ieucine/isoleucine, phenyIaIanine/tyrosine, lysine/arginine, aIanine/valine,
glutamate/aspartate, and asparagine/glutamine. In some embodiments, a conservative
amino acid substitution can be a tution of any native e in a protein with alanine,
as used in, for example, alanine ng mutagenesis. In some embodiments, a
conservative substitution is made that has a positive value in the PAM250 log-likelihood
matrix disclosed in Gonnet et al. ) Exhaustive Matching of the Entire Protein
ce Database, Science 256:1443~45), hereby incorporated by reference. in some
embodiments, the substitution is a moderately conservative substitution n the
substitution has a nonnegative value in the PAM250 log—likelihood matrix.
Thus, also encompassed by the invention is a cally modified non-human
animal whose genome comprises a nucleotide sequence encoding a human or humanized
MHC | polypeptide and/or [32 microglobulin polypeptide, wherein the polypeptide(s)
comprises conservative amino acid substitutions of the amino acid sequence(s) described
herein.
One d in the art would understand that in addition to the nucleic acid
residues encoding a human or humanized MHC l polypeptide and/or 02 lobulin
described herein, due to the racy of the genetic code, other c acids may
encode the ptide(s) of the invention. Therefore, in addition to a genetically modified
non-human animal that comprises in its genome a nucleotide sequence encoding MHC l
and/or [32 microglobulin polypeptide(s) with conservative amino acid substitutions, a non—
human animal whose genome comprises a tide sequence(s) that differs from that
described herein due to the degeneracy of the genetic code is also provided.
The term “identity” when used in connection with sequence includes identity as
determined by a number of different algorithms known in the art that can be used to
measure nucleotide and/or amino acid sequence identity. ln some embodiments described
herein, identities are determined using a ClustalW v. 1.83 (slow) alignment employing an
open gap penalty of 10.0, an extend gap penalty of 0.1, and using a Gonnet similarity matrix
(MacVectorTM 10.0.2, MacVector lnc., 2008). The length of the sequences compared with
respect to identity of sequences will depend upon the particular sequences. In various
embodiments, identity is determined by comparing the sequence of a mature protein from its
N—terminal to its C-terminal. In various ments when comparing a chimeric
human/non-human sequence to a human sequence, the human portion of the chimeric
human/non—human sequence (but not the non-human portion) is used in making a
comparison for the purpose of ascertaining a level of identity between a human ce
and a human portion of a chimeric human/non-human sequence (e.g., ing a human
ectodomain of a ic human/mouse protein to a human ectodomain of a human
protein).
2012/062042
The terms “homology” or “homologous” in reference to sequences, e.g.,
nucleotide or amino acid sequences, means two ces which, upon optimal alignment
and comparison, are identical in at least about 75% of nucleotides or amino acids, at least
about 80% of nucleotides or amino acids, at least about 90-95% nucleotides or amino acids,
e.g., greater than 97% nucleotides or amino acids. One skilled in the art would understand
that, for optimal gene targeting, the targeting construct should contain arms gous to
endogenous DNA sequences (i.e., "homology arms”); thus, homologous recombination can
occur between the targeting construct and the targeted endogenous sequence.
The term "operably linked" refers to a juxtaposition wherein the components so
described are in a relationship ting them to function in their intended manner. As
such, a nucleic acid sequence encoding a protein may be operably linked to regulatory
sequences (e.g., promoter, enhancer, silencer sequence, etc.) so as to retain proper
transcriptional regulation. In addition, various portions of the chimeric or humanized protein
of the invention may be operably linked to retain proper folding, processing, targeting,
expression, and other functional properties of the protein in the cell. Unless stated
otherwise, s domains of the chimeric or zed proteins of the invention are
operably linked to each other.
The term “MHC l complex” or the like, as used herein, includes the complex
between the MHC l on chain polypeptide and the BZ-microglobulin ptide. The term
“MHC l ptide” orthe like, as used herein, includes the MHC l a chain polypeptide
alone. Typically, the terms “human MHC” and “HLA” can be used interchangeably.
The term “replacement” in reference to gene replacement refers to placing
exogenous c material at an endogenous genetic locus, thereby replacing all or a
portion of the endogenous gene with an orthologous or homologous nucleic acid sequence.
As trated in the Examples below, nucleic acid sequences of endogenous loci
encoding portions of mouse MHC l and [32 microglobulin ptides were replaced by
nucleotide sequences encoding ns of human MHC | and [32 microglobulin
polypeptides, respectively.
“Functional” as used herein, e.g., in reference to a functional polypeptide, refers
to a polypeptide that retains at least one biological activity ly associated with the
native protein. For example, in some embodiments of the invention, a replacement at an
endogenous locus (e.g., replacement at an endogenous non—human MHC l and/or [32
microglobulin locus) results in a locus that fails to express a onal endogenous
polypeptide.
Several aspects described herein below for the genetically modified MHC l non-
human animals, e.g., animal type; animal strains; cell types; screening, detection and other
methods; methods of use; etc., will be applicable to the genetically engineered {32
microglobulin and MHC l/[32 microglobulin animals.
cally Modified MHC I Animals
in various embodiments, the invention generally provides genetically modified
non-human animals that comprise in their genome a nucleotide sequence encoding a
human or humanized MHC | polypeptide; thus, the animals s a human or humanized
MHC l polypeptide.
MHC genes are categorized into three classes: class I, class ll, and class lll, all
of which are encoded either on human chromosome 6 or mouse chromosome 17. A
tic of the relative organization of the human and mouse MHC classes is presented in
Fle. 2 and 3, respectively. The MHC genes are among the most polymorphic genes of the
mouse and human genomes. MHC rphisms are presumed to be ant in
providing evolutionary age; changes in ce can result in differences in peptide
binding that allow for better presentation of pathogens to cytotoxic T cells.
MHC class i n comprises an extracellular domain (which comprises three
domains: a1, a2, and a3), a transmembrane domain, and a cytoplasmic tail. The 0:1 and (12
domains form the peptide-binding cleft, while the Q3 cts with fiZ-microglobulin.
In addition to its interaction with BZ—microglobulin, the Q3 domain interacts with the
TCR co-receptor CD8, facilitating antigen—specific activation. Although binding of MHC class
i to CD8 is about 100—fold weaker than g of TCR to MHC class I, CD8 binding
enhances the affinity of TCR binding. Wooldridge et al. (2010) MHC Class I Molecules with
Superenhanced CD8 Binding Properties Bypass the Requirement for Cognate TCR
Recognition and Nonspecifically Activate CTLs, J. Immunol. 184:3357—3366. Interestingly,
sing MHC class i binding to CD8 abrogated antigen specificity in CTL activation. Id.
CD8 binding to MHC class I molecules is species-specific; the mouse homolog of
CD8, Lyt-2, was shown to bind H-2Dd molecules at the a3 domain, but it did not bind HLA-A
molecules. Connolly et al. (1988) The Lyt-2 Molecule Recognizes Residues in the Class I
a3 Domain in neic Cytotoxic T Cell Responses, J. Exp. Med. 168:325-341.
Differential binding was presumably due to CDR-like determinants (CDR1- and CDR2—Iike)
on CD8 that was not conserved n humans and mice. Sanders et al. (1991) Mutations
in CD8 that Affect lnteractions with HLA Class i and Monoclonal Anti-CD8 Antibodies, J.
Exp. Med. 174:371-379; Vitiello et al. (1991) Analysis of the HLA-restricted influenza-specific
WO 63346
Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse
Class I Major Histocompatibility Complex, J. Exp. Med. 173:1007-1015; and, Gao et al.
(1997) Crystal structure of the complex between human CD8aa and HLA—A2, Nature
387:630—634. it has been reported that CD8 binds HLA—A2 in a conserved region of the 0:3
domain (at position 223-229). A single substitution (V245A) in HLA-A d binding of
CD8 to HLA-A, with a concomitant large reduction in T cell-mediated lysis. Salter et al.
(1989), Polymorphism in the as domain of HLA—A molecules affects binding to CDB, Nature
338:345-348. in general, polymorphism in the (x3 domain of HLA—A les also affected
binding to CD8. Id. in mice, amino acid substitution at residue 227 in H—2Dd affected the
binding of mouse Lyt—2 to H-2D", and cells transfected with a mutant H-2Dd were not lysed
by CDB+ T cells. Potter et al. (1989) tution at e 227 of H—2 class l molecules
abrogates ition by CD8-dependent, but not CD8-independent, xic T
lymphocytes, Nature 337:73-75.
ore, due to species specificity of interaction between the MHC class l a3
domain and CD8, an MHC l x comprising a replacement of an H-2K a3 domain with a
human HLA—AZ a3 domain was nonfunctional in a mouse (i.e., in vivo) in the absence of a
human CD8. in animals transgenic for HLA—A2, substitution of human a3 domain for the
mouse (13 domain resulted in restoration of T cell response. lrwin et al. (1989) Species-
restricted interactions n CD8 and the a3 domain of class I influence the magnitude of
the xenogeneic response, J. Exp. Med. 91—1101;Vitiello et al. (1991), supra.
The transmembrane domain and cytoplasmic tail of mouse MHC class l proteins
also have important functions. One on of MHC | transmembrane domain is to facilitate
modulation by HLA—A2 of homotypic cell adhesion (to enhance or inhibit adhesion),
presumably as the result of cross-linking (or ligation) of surface MHC molecules. Wagner et
al. (1994) Ligation of MHC Class l and Class ll Molecules Can Lead to Heterologous
Desensitization of Signal Transduction Pathways That Regulate Homotypic Adhesion in
Human Lymphocytes, J. lmmunol. 152:5275—5287. Cell adhesion can be affected by mAbs
that bind at diverse epitopes of the HLA-A2 molecule, suggesting that there are multiple
sites on HLA—A2 implicated in modulating homotypic cell adhesion; depending on the
epitope bound, the affect can be to enhance or to inhibit HLA-AZ-dependent adhesion. Id.
The cytoplasmic tail, encoded by exons 6 and 7 of the MHC l gene, is reportedly
necessary for proper expression on the cell surface and for LlR1-mediated inhibition of NK
cell cytotoxicity. Gruda et al. (2007) intracellular Cysteine Residues in the Tail of MHC
Class l ns Are Crucial for Extracellular ition by Leukocyte lg-Like Receptor 1, J.
lmmunol. 179:3655—3661. A asmic tail is required for multimerizaton of at least some
MHC l molecules through formation of ide bonds on its cysteine residues, and thus
may play a role in clustering and in recognition by NK cells. Lynch et al. (2009) Novel MHC
Class l Structures on Exosomes, J. lmmunol. 183:1884-1891.
The cytoplasmic domain of HLA-A2 contains a constitutively phosphorylated
serine residue and a phosphorylatable tyrosine, although—~in Jurkat cells—mutant HLA—AZ
molecules lacking a asmic domain appear normal with respect to expression,
cytoskeletal association, aggregation, and endocytic internalization. Gur et al. (1997)
Structural Analysis of Class l MHC Molecules: The Cytoplasmic Domain is Not Required for
Cytoskeletal Association, Aggregation, and Internalization, Mol. lmmunol. 34(2):125-132.
Truncated HLA—A2 molecules lacking the cytoplasmic domain are apparently normally
expressed and ate with [32 lobulin. Id.
However, several studies have demonstrated that the cytoplasmic tail is critical in
intracellular trafficking, dendritic cell (DC)-mediated antigen tation, and CTL priming.
A ne residue encoded by exon 6 was shown to be required for MHC l trafficking
through endosomal tments, presentation of exogenous antigens, and CTL priming;
while deletion of exon 7 caused enhancement of anti—viral CTL responses. Lizee et al.
(2003) Control of Dendritic Cross-Presentation by the Major Histocompatibility Complex
Class l Cytoplasmic , Nature lmmunol. 4:1065-73; Basha et al. (2008) MHC Class I
Endosomal and Lysosomal cking Coincides with Exogenous Antigen Loading in
Dendritic Cells, PLoS ONE 3: e3247; and Rodriguez-Cruz et al. (2011) Natural Splice
Variant of MHC Class | Cytoplasmic Tail Enhances tic Cell-induced CD8+ T-Cell
Responses and Boosts Anti-Tumor Immunity, PLoS ONE 6322939.
ln s embodiments, the invention provides a cally modified non-
human animal (e.g., mouse, rat, rabbit, etc.) that comprises in its genome a nucleotide
sequence encoding a human or humanized MHC class l polypeptide. The non-human
animal may comprise in its genome a nucleotide sequence that encodes an MHC l
polypeptide that is partially human and partially non-human, e.g., a non—human animal that
expresses a chimeric human/non—human MHC l polypeptide. In one aspect, the non—human
animal only expresses the human or humanized MHC | polypeptide, e.g., chimeric
human/non—human MHC l polypeptide, and does not express an endogenous man
MHC l protein from an endogenous MHC l locus.
In one embodiment, the ic human/non-human MHC l ptide
comprises in its human portion a e binding domain of a human MHC l polypeptide. in
one aspect, the human portion of the chimeric polypeptide comprises an extracellular
domain of a human MHC l. In this embodiment, the human portion of the chimeric
polypeptide comprises an extracellular domain of an a chain of a human MHC i. In one
embodiment, the human portion of the chimeric polypeptide comprises a1 and a2 domains
of a human MHC I. in another embodiment, the human portion of the chimeric ptide
comprises a1, a2, and a3 domains ofa human MHC l.
The human or humanized MHC l polypeptide may be d from a functional
human HLA le encoded by any of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G
loci. A list of commonly used HLA antigens is described in Shankarkumar et al. ((2004) The
Human Leukocyte Antigen (HLA) System, lnt. J. Hum. Genet. 4(2):91-103), incorporated
herein by nce. Shankarkumar et al. also present a brief explanation of HLA
nomenclature used in the art. onal information regarding HLA nomenclature and
various HLA alleles can be found in Holdsworth et al. (2009) The HLA dictionary 2008: a
summary of HLA-A, —B, -C, -DRB1/3/4/5, and DQB1 alleles and their association with
serologically defined HLA-A, -B, -C, -DR, and -DQ antigens, Tissue Antigens 73295—170,
and a recent update by Marsh et al. (2010) Nomenclature for factors of the HLA system,
2010, Tissue Antigens 751291-455, both incorporated herein by reference. Thus, the human
or humanized MHC l polypeptide may be derived from any functional human HLA class i
molecules described therein.
in one specific aspect, the human or humanized MHC l polypeptide is d
from human HLA-A. in a specific embodiment, the HLA-A polypeptide is an HLA—A2
polypeptide (e.g., and HLA-A21 polypeptide). in one embodiment, the HLA—A polypeptide is
a polypeptide encoded by an HLA—A*0201 allele, e.g., HLA-A*02:01 :01 :01 allele. The HLA-
A*0201 allele is commonly used t the North American population. Although the
present es describe this particular HLA sequence, any suitable HLA-A sequence is
assed herein, e.g., polymorphic variants of HLA-A2 exhibited in human tion,
sequences with one or more conservative or non-conservative amino acid modifications,
nucleic acid sequences differing from the sequence bed herein due to the degeneracy
of c code, etc.
in one aspect, a non-human animal that expresses a human HLA—A2 sequence is
provided, wherein the human HLA-A2 sequence comprises one or more vative or
non—conservative modifications.
in one aspect, a non—human animal that expresses a human HLA-A2 sequence is
provided, wherein the human HLA-A2 sequence is at least about 85%, 90%, 95%, 96%,
97%, 98%, or 99% identical to a human HLA-A2 sequence. in a specific embodiment, the
human HLA-A2 sequence is at least about 90%, 95%, 96%, 97%, 98%, or 99% identical to
the human HLA-A2 sequence described in the Examples. in one embodiment, the human
HLA-AZ sequence ses one or more conservative substitutions. in one embodiment,
the human HLA—A2 sequence comprises one or more non-conservative substitutions.
In another specific aspect, the human or humanized MHC l polypeptide is derived
from human MHC l selected from HLA—B and HLA—C. In one aspect, the human or
humanized MHC I is derived from HLA-B, e.g., HLA-BZ7.
in one aspect, the non-human portion of the chimeric human/non—human MHC l
polypeptide comprises transmembrane and/or cytoplasmic s of the non—human MHC
I polypeptide. in one embodiment, the non-human animal is a mouse, and the non-human
MHC l polypeptide is ed from H-2K, H—2D, and H-2L. In one embodiment, the non—
human MHC l polypeptide is H-2K, e.g., H-2Kb. gh specific H-2K ces are
described in the Examples, any suitable H-2K sequences, e.g., polymorphic ts,
conservative/non-conservative amino acid substitutions, etc., are encompassed herein.
The man animal described herein may comprise in its genome a
nucleotide sequence encoding a human or humanized MHC l polypeptide, e.g., chimeric
human/non-human MHC l ptide, wherein the tide sequence encoding such
polypeptide is located at an endogenous non-human MHC l locus (e.g., H-2K locus). In one
aspect, this results in a replacement of an endogenous MHC l gene or a n thereof with
a nucleotide sequence encoding a human or humanized MHC l ptide, e.g., a chimeric
gene encoding a chimeric human/non-human MHC l polypeptide described herein. in one
embodiment, the replacement comprises a replacement of an endogenous nucleotide
sequence encoding a non-human MHC I peptide binding domain or a non-human MHC l
extracellular domain with a human tide sequence (e.g., HLA—AZ nucleotide sequence)
ng the same. in this embodiment, the replacement does not comprise a replacement
of an MHC l sequence ng transmembrane and/or cytoplasmic domains of a non-
human MHC l polypeptide (e.g., H-2K polypeptide). Thus, the non-human animal contains
chimeric human/non-human nucleotide sequence at an endogenous non—human MHC l
locus, and expresses chimeric human/non-human MHC polypeptide from the endogenous
non—human MHC l locus.
A chimeric human/non—human ptide may be such that it comprises a
human or a non—human leader (signal) sequence. in one embodiment, the ic
polypeptide comprises a non—human leader sequence of an endogenous MHC I protein. in
another embodiment, the chimeric polypeptide comprises a leader sequence of a human
MHC l protein, e.g., HLA—A2 protein (for instance, HLA—A2.t leader sequence). Thus, the
nucleotide sequence encoding the chimeric MHC | polypeptide may be operably linked to a
nucleotide sequence encoding a human MHC I leader sequence.
A chimeric human/non-human MHC I polypeptide may comprise in its human
portion a complete or substantially complete extracellular domain of a human MHC |
polypeptide. Thus, the human n may comprise at least 80%, preferably at least 85%,
more preferably at least 90%, e.g., 95% or more of the amino acids encoding an
extracellular domain of a human MHC l polypeptide (e.g., HLA—AZ polypeptide). in one
e, substantially te extracellular domain of the human MHC | polypeptide lacks
a human MHC l leader sequence. In another example, the chimeric human/non-human
MHC l polypeptide comprises a human MHC | leader sequence.
Moreover, the chimeric MHC l polypeptide may be expressed under the control of
endogenous non-human regulatory elements, e.g., rodent MHC l regulatory animals. Such
arrangement will facilitate proper expression of the chimeric MHC l polypeptide in the non—
human animal, e.g., during immune response in the non-human animal.
The genetically modified non-human animal may be selected from a group
consisting ofa mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer, sheep, goat,
chicken, cat, dog, ferret, primate (e.g., marmoset, rhesus monkey). Forthe non-human
animals where suitable genetically modifiable ES cells are not readily available, other
s are employed to make a non—human animal comprising the genetic cation.
Such methods e, e.g., modifying a non—ES cell genome (e.g., a last or an
induced pluripotent cell) and employing r transfer to transfer the modified genome to a
suitable cell, e.g., an oocyte, and gestating the modified cell (e.g., the ed oocyte) in a
non-human animal under suitable conditions to form an embryo.
In one aspect, the non—human animal is a mammal. in one aspect, the nonhuman
animal is a small mammal, e.g., of the superfamily Dipodoidea or Muroidea. In one
embodiment, the geneticaily modified animal is a rodent. in one embodiment, the rodent is
ed from a mouse, a rat, and a hamster. in one embodiment, the rodent is selected
from the superfamily ea. in one embodiment, the cally modified animal is from
a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster,
New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested
rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice),
anthomyidae (e.g., spiny dormice), and idae (e.g., mole rates, bamboo rats,
and zokors). in a specific embodiment, the genetically modified rodent is selected from a
true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat. in one
embodiment, the genetically modified mouse is from a member of the family Muridae. In
one embodiment, the animal is a rodent. in a specific embodiment, the rodent is selected
from a mouse and a rat. in one ment, the non-human animal is a mouse.
2012/062042
in a specific embodiment, the non-human animal is a rodent that is a mouse of a
C57BL strain selected from CS7BL/A, C57BL/An, C57BL/GrFa, 057BL/KaLwN, C57BL/6,
C57BL/6J, CS7BL/6ByJ, C57BL/6NJ, 057BL/10, CS7BL/108c8n, CS7BL/1OCr, and
C57BL/Ola. In another embodiment, the mouse is a 129 strain selected from the group
consisting of a strain that is 129P1, 129P2, 129P3, 129X1, 12981 (e.g., 12981/8V,
12981/8vlm), 12982, 12984, 12985, 12989/8vaH, 12986 (129/8vaTac), 12987, 12988,
129T1, 129T2 (see, e.g., Festing et al. (1999) Revised nomenclature for strain 129 mice,
Mammalian Genome 10:836, see also, Auerbach et al (2000) Establishment and Chimera
Analysis of 129/8va— and C57BL/6-Derived Mouse nic Stem Cell . In a
ic embodiment, the genetically modified mouse is a mix of an aforementioned 129
strain and an aforementioned 057BL/6 strain. in another specific ment, the mouse is
a mix of aforementioned 129 s, or a mix of aforementioned BL/6 strains. In a specific
embodiment, the 129 strain of the mix is a 12986 (129/8vaTac) strain. in another
embodiment, the mouse is a BALB strain, e.g., BALB/c strain. in yet another embodiment,
the mouse is a mix of a BALB strain and another aforementioned .
in one embodiment, the man animal is a rat. in one embodiment, the rat
is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344,
F6, and Dark Agouti. in one embodiment, the rat strain is a mix of two or more strains
selected from the group consisting of Wistar, LEA, Sprague , Fischer, F344, F6, and
Dark Agouti.
Thus, in one embodiment, the invention s to a genetically modified mouse
that comprises in its genome a nucleotide sequence encoding a chimeric human/mouse
MHC l polypeptide, wherein a human portion of the chimeric polypeptide comprises a
peptide binding domain or an extracellular domain of a human MHC l (e.g., human HLA-A,
e.g., human HLA~A2, e.g., human HLA—A2.1). in some embodiments, the mouse does not
express a peptide binding or an extracellular domain of an endogenous mouse polypeptide
from its endogenous mouse locus. The peptide binding domain of the human MHC i may
comprise (11 and d2 domains. Alternatively, the e binding domain of the human MHC
i may comprise «11, a2, and (13 domains. In one aspect, the extracellular domain of the
human MHC 1 comprises an extracellular domain of a human MHC l 0: chain. in one
embodiment, the endogenous mouse locus is an H-2K (e.g., H-2Kb) locus, and the mouse
portion of the chimeric polypeptide comprises transmembrane and cytoplasmic domains of a
mouse H-2K (e.g., H—2Kb) polypeptide.
Thus, in one embodiment, a cally modified mouse is provided, n the
mouse comprises at an endogenous H-2K (e.g., H—2Kb) locus a nucleotide sequence
encoding a chimeric mouse MHC I polypeptide, wherein a human portion of the
chimeric polypeptide comprises an extracellular domain of a human HLA—A2 (e.g., HLA-
A2.1) polypeptide and a mouse portion comprises transmembrane and cytoplasmic domains
of a mouse H-2K (e.g., H-2Kb) polypeptide. In one aspect, the mouse does not express an
extracellular domain of the mouse H-2K (e.g., H-2Kb) ptide from an endogenous MHC
I locus. In one embodiment, the mouse expresses a ic HLA—A2/H-2K (e.g., a chimeric
HLA-A2.1/H-2Kb) polypeptide from an endogenous H-2K (e.g., H—2Kb) locus. In various
embodiments, expression of the chimeric gene is under control of endogenous mouse MHC
class l regulatory elements. In some aspects, the mouse comprises two copies of the
chimeric MHC l locus containing a nucleotide sequence encoding a chimeric HLA-A2/H-2K
polypeptide; while in other aspects, the mouse comprises one copy of the chimeric MHC I
locus containing a nucleotide sequence encoding a chimeric HLA—A2/H-2K polypeptide.
Thus, the mouse may be homozygous or heterozygous for the nucleotide sequence
encoding the chimeric HLA—AZ/H-ZK polypeptide.
In some ments described herein, a mouse is provided that comprises a
chimeric MHC | locus d at an endogenous mouse H-2K locus. The chimeric locus
comprises a tide sequence that encodes an extracellular domain of a human HLA—AZ
protein, e.g., d1, <12, and d3 domains of a human HLA—A2 gene. The ic locus lacks a
nucleotide sequence that encodes an extracellular domain of a mouse H—2K protein (e.g.,
(11, a2, and a3 domains of the mouse H-2K). In one , the chimeric locus lacks a
nucleotide sequence that encodes a leader peptide, a1, a2, and a3 domains of a mouse H—
2K; and comprises a leader peptide, a1, a2, and d3 domains of a human HLA-A2, and
transmembrane and cytoplasmic s of a mouse H—2K. The various domains of the
chimeric locus are operably linked to each other such that the chimeric locus expresses a
onal chimeric human/mouse MHC I protein.
In s embodiments, a non-human animal, e.g., a rodent (e.g., a mouse or a
rat), that expresses a functional chimeric MHC I protein from a chimeric MHC I locus as
described herein displays the chimeric n on a cell surface. In one ment, the
non-human animaI expressed the chimeric MHC l protein on a cell surface in a cellular
distribution that is the same as observed in a human. In one aspect, the cell displays a
peptide fragment (an antigen nt) bound to an extracellular portion (e.g., human HLA-
AZ extracellular portion) of the chimeric MHC l protein. In an embodiment, the extracellular
portion of such chimeric protein interacts with other proteins on the surface of said cell, e.g.,
BZ—microglobulin.
In various embodiments, a cell displaying the chimeric MHC | protein, e.g., HLAA2
/H-2K protein, is a nucleated cell. in various aspects, the cell is an antigen-presenting cell
(APC). Although most cells in the body can t an antigen in the context of MHC l,
some nonlimiting examples of antigen presenting cells include macrophages, dendritic cells,
and B cells. Other antigen presenting cells, including professional and nonprofessional
APCs, are known in the art, and are encompassed herein. in some embodiments, the cell
displaying the chimeric MHC l protein is a tumor cell, and a peptide fragment presented by
the chimeric protein is derived from a tumor. In other embodiments, the peptide fragment
presented by the ic MHC l n is derived from a pathogen, e.g., a bacterium or a
virus.
The chimeric MHC l protein described herein may interact with other proteins on
the surface of the same cell or a second cell. in some embodiments, the ic MHC l
protein interacts with endogenous non-human proteins on the surface of said cell. The
chimeric MHC l protein may also interact with human or humanized proteins on the surface
of the same cell or a second cell.
On the same cell, HLA class l les may functionally interact with both non-
human (e.g., rodent, e,g., mouse or rat) and human BZ—microglobulin. Thus, in one
embodiment, the chimeric MHC l protein, e.g., /H-2K protein, interacts with a mouse
fiZ—microglobuiin. gh interaction between some human HLA class I molecules and
mouse BZ-microglobulin is possible, it nevertheless may be greatly reduced in comparison to
interaction between human HLA class l and human fiZ-microglobulin. Thus, in the absence
of human BZ—microglobulin, expression of human MHC l on the cell surface may be reduced.
Perarnau et al. (1988) Human BZ-microglobulin Specifically Enhances urface
Expression of HLA Class l Molecules in Transfected Murine Cells, J. Immunol. 141:1383-89.
Other HLA molecules, e.g., HLA-827, do not interact with mouse fiZ-microglobulin; see, e.g.,
Tishon et al. (2000) Transgenic Mice Expressing Human HLA and CD8 Molecules Generate
HLA-Restricted Measles Virus Cytotoxic T Lymphocytes of the Same Specificity as Humans
with Natural s Virus ion, Virology 275286-293, which reports that HLA-827
on in transgenic mice requires both human BZ—microglobulin and human CD8.
Therefore, in another embodiment, the chimeric MHC l protein interacts with a human or
humanized fiZ—microglobulin. in some such embodiments, as bed herein below, the
non-human animal, e.g., a rodent (e.g., a mouse or a rat), comprises in its genome a human
or humanized BZ-microglobulin gene, and the animal ses a functional human or
humanized fiZ—microglobulin polypeptide; ore, the chimeric MHC l n interacts with
a human or humanized BZ-microglobulin polypeptide.
In various aspects, the chimeric protein (e.g., /H-2K n) also interacts
with proteins on the surface of a second cell (through its extracellular portion). The second
cell may be a cell of a non-human, e.g., a mouse, or a human origin. The second cell may
be derived from the same non-human animal or the same man animal specie as the
cell sing the chimeric MHC l ptide. Nonlimiting examples of proteins with which
the extracellular portion of a chimeric protein (e.g., HLA—A2/H-2K) may interact include T cell
receptor (TCR) and its co-receptor CD8. Thus, a second cell may be a T cell. in addition,
the extracellular portion of the chimeric MHC l protein may bind a protein on the surface of
Natural Killer (NK) cells, e.g., killer globulin receptors (Kle) on the surface of NK
cells.
A T cell or NK cell may bind a complex formed between the chimeric MHC l
polypeptide and its displayed peptide fragment. Such binding may result in T cell activation
or inhibition of NK—mediated cell killing, respectively. One hypothesis is that NK cells have
evolved to kill either infected or tumor cells that have evaded T cell mediated cytotoxicity by
downregulating their MHC l complex. However, when MHC l complex is expressed on cell
surface, NK cell receptors recognize it, and NK-mediated cell g is inhibited. Thus, in
some aspects, when an NK cell binds a complex formed between the chimeric MHC l
polypeptide (e.g., HLA—A2/H-2K polypeptide) and a displayed peptide fragment on the
surface of infected or tumor cell, the NK—mediated cell g is inhibited.
In one example, the ic MHC | polypeptide described herein, e.g., a
chimeric HLA—A2/H-2K polypeptide, interacts with CD8 protein on the surface of a second
cell. In one embodiment, the chimeric HLA—A2/H—2K polypeptide interacts with endogenous
rodent (e.g., mouse or rat) CD8 protein on the surface of a second cell. in one embodiment,
the second cell is a T cell. In another embodiment, the second cell is engineered to express
CD8. in n aspects, the chimeric HLA-A2/H-2K polypeptide cts with a human CD8
on the surface of the second cell (e.g., a human cell or a rodent cell). in some such
embodiments, the man , e.g., a mouse or a rat, comprises a human CD8
transgene, and the mouse or the rat expresses a functional human CD8 protein.
The chimeric MHC l ptide described herein may also interact with a nonhuman
(e.g., a mouse or a rat) TCR, a human TCR, or a humanized TCR on a second cell.
The chimeric MHC l polypeptide may interact with an endogenous TCR (e.g., mouse or rat
TCR) on the surface of a second cell. The chimeric MHC l polypeptide may also interact
with a human or humanized TCR expressed on the surface of a second cell, wherein the cell
is derived from the same animal or animal specie (e.g., mouse or rat) as the cell expressing
the chimeric MHC l polypeptide. The chimeric MHC l ptide may interact with a human
TCR expressed on the surface of a human cell.
In addition to genetically engineered non-human animals, a non—human embryo
(e.g., a rodent embryo, e.g., mouse or a rat embryo) is also provided, wherein the embryo
comprises a donor ES cell that is derived from a man animal (e.g., a rodent, e.g., a
mouse or a rat) as described . In one aspect, the embryo comprises an ES donor cell
that comprises the chimeric MHC I gene, and host embryo cells.
Also provided is a tissue, wherein the tissue is derived from a man animal
(e.g., a mouse or a rat) as described herein, and expresses the chimeric MHC l polypeptide
(e.g., HLA—AZ/H-ZK polypeptide).
In addition, a non-human cell isolated from a non-human animal as described
herein is provided. In one embodiment, the cell is an ES cell. In one embodiment, the cell is
an antigen-presenting cell, e.g., dendritic cell, macrophage, B cell. In one embodiment, the
cell is an immune cell. In one embodiment, the immune cell is a lymphocyte.
Also provided is a non-human cell comprising a chromosome or fragment thereof
of a non-human animal as described herein. In one embodiment, the non-human cell
comprises a s of a non—human animal as described herein. In one embodiment, the
man cell comprises the chromosome or fragment thereof as the result of a r
transfer.
In one aspect, a non-human induced pluripotent cell comprising gene encoding a
chimeric MHC I polypeptide (e.g., HLA-AZ/H-ZK polypeptide) as described herein is
provided. In one embodiment, the induced pluripotent cell is derived from a man
animal as described herein.
In one aspect, a hybridoma or quadroma is provided, derived from a cell of a non-
human animal as described herein. In one embodiment, the man animal is a mouse
or rat.
Also provided is a method for making a genetically engineered non-human
animal (e.g., a genetically engineered rodent, e.g., a mouse or a rat) described herein. The
method for making a genetically ered non-human animal results in the animal whose
genome ses a nucleotide sequence encoding a ic MHC I polypeptide. In one
embodiment, the method results in a genetically ered mouse, whose genome
comprises at an endogenous MHC I locus, e.g., H-2K locus, a nucleotide sequence
encoding a chimeric human/mouse MHC I polypeptide, wherein a human portion of the
chimeric MHC I polypeptide comprises an extracellular domain of a human HLA—AZ and a
mouse portion ses transmembrane and cytoplasmic domains of a mouse H-2K. In
some embodiments, the method utilizes a targeting construct made using GENE®
technology, ucing the construct into ES cells, and introducing targeted ES cell clones
into a mouse embryo using MOUSE® logy, as described in the Examples. In
one embodiment, the ES cells are a mix of 129 and 057BL/6 mouse strains; in another
embodiment, the ES cells are a mix of BALB/c and 129 mouse strains.
Thus, a nucleotide construct used for generating genetically engineered non-
human animals described herein is also provided. In one aspect, the nucleotide construct
comprises: 5’ and 3’ non—human gy arms, a human DNA fragment comprising human
HLA-A gene sequences, and a ion cassette flanked by recombination sites. In one
embodiment, the human DNA fragment is a genomic fragment that ses both s
and exons of a human HLA—A gene. In one embodiment, the non—human homology arms
are homologous to a non-human MHC class I locus (e.g., a mouse H—2K locus).
In one embodiment, the genomic fragment comprises a human HLA-A , an
a1 domain, an a2 domain and an a3 domain coding sequence. In one embodiment, the
human DNA fragment comprises, from 5’ to 3’: an HLA—A leader sequence, an HLA-A
leader/a1 intron, an HLA-A a1 exon, an HLA-A a1-cx2 intron, an HLA-A a2 exon, an HLA—A
a2-a3 intron, and an HLA-A a3 exon.
A selection cassette is a nucleotide sequence inserted into a targeting construct
to facilitate selection of cells (e.g., ES cells) that have integrated the construct of interest. A
number of suitable ion cassettes are known in the art. Commonly, a selection cassette
enables positive selection in the presence of a particular otic (e.g., Neo, Hyg, Pur, CM,
Spec, etc.). In addition, a selection cassette may be flanked by ination sites, which
allow deletion of the selection cassette upon treatment with recombinase enzymes.
Commonly used recombination sites are loxP and Fn‘, recognized by Cre and Flp enzymes,
tively, but others are known in the art.
In one embodiment, the selection cassette is located at the 5’ end the human
DNA fragment. In another embodiment, the selection cassette is located at the 3’ end of the
human DNA fragment. In another embodiment, the selection cassette is located within the
human DNA fragment. In another embodiment, the selection cassette is located within an
intron of the human DNA fragment. In another embodiment, the selection cassette is
located within the a2-oc3 intron.
In one embodiment, the 5’ and 3’ non-human homology arms comprise genomic
sequence at 5’ and 3’ locations of an endogenous man (e.g., ) MHC class I
gene locus, respectively (e.g., 5’ of the first leader sequence and 3’ of the a3 exon of the
non-human MHC I gene). In one embodiment, the endogenous MHC class I locus is
selected from mouse H—2K, H—2D and H-2L. In a specific embodiment, the endogenous
MHC class I locus is mouse H-2K.
In one aspect, a tide construct is provided, comprising, from 5’ to 3’: a 5’
homology arm containing mouse genomic ce 5’ of the endogenous mouse H-2K
locus, a first human DNA nt comprising a first genomic sequence of an HLA—A gene,
a 5’ recombination sequence site (e.g., loxP), a selection cassette, a 3’ recombination
sequence site (e.g., onP), a second human DNA fragment sing a second c
sequence of an HLA-A gene and a 3’ homology arm containing mouse genomic sequence 3’
of an nous H-2K a3 exon. in one embodiment, the nucleotide construct comprises,
from 5’ to 3’: a 5’ homology arm containing mouse genomic sequence 5’ of the endogenous
mouse H—2K locus, a human genomic sequence including an HLA—A , an HLA—A
leader/a1 intron sequence, an HLA—A a1 exon, an HLA-A 2 intron, an HLA—A a2 exon,
a first 5’ portion of an a2-a3 intron, a selection cassette flanked by recombination sites, a
second 3’ portion of an a2-oc3 intron, an HLA—A a3 exon, and a 3’ homology arm containing
non—mouse genomic sequence 3’ of the endogenous mouse H—2K a3 exon. In one
embodiment, a 5’ homology arm sequence is set forth in SEQ lD NO:1, and a 3’ homology
arm sequence is set forth in SEQ lD NO:2.
Upon completion of gene targeting, ES cells or genetically modified non—human
animals are screened to m successful incorporation of exogenous tide sequence
of interest or expression of exogenous polypeptide. Numerous techniques are known to
those skilled in the art, and include (but are not limited to) rn blotting, long PCR,
quantitative PCT (e.g., real-time PCR using TAQMAN®), fluorescence in situ hybridization,
Northern blotting, flow cytometry, Western analysis, cytochemistry,
immunohistochemistry, etc. in one example, non-human animals (e.g., mice) bearing the
genetic modification of interest can be identified by screening for loss of mouse allele and/or
gain of human allele using a modification of allele assay described in Valenzuela et al.
(2003) High-throughput ering of the mouse genome coupled with high-resolution
expression analysis, Nature Biotech. 652—659. Other assays that identify a specific
nucleotide or amino acid sequence in the genetically modified animals are known to those
d in the art.
The disclosure also provides a method of modifying an MHC l locus of a nonhuman
animal to express a chimeric human/non-human MHC l ptide described
herein. In one embodiment, the invention provides a method of modifying an MHC l locus of
a mouse to express a chimeric human/mouse MHC l polypeptide wherein the method
ses replacing at an endogenous MHC l locus a nucleotide sequence encoding a
peptide binding domain of a mouse MHC polypeptide with a nucleotide sequence encoding
a peptide binding domain of a human MHC l polypeptide. in some aspects, a nucleotide
sequence of an extracellular domain of a mouse MHC l is replaced by a nucleotide
sequence of an extracellular domain of a human MHC l. The mouse may fail to express the
peptide binding or the extracellular domain of the mouse MHC l from an endogenous MHC l
locus. in some embodiments, a nucleotide sequence of an extracellular domain of a mouse
H-2K is ed by a tide sequence of an extracellular domain of a human HLA-A2,
such that the modified mouse MHC l locus expresses a chimeric HLA—A2/H-2K polypeptide.
in one aspect, a method for making a chimeric human HLA class i/non-human
MHC class I le is ed, comprising expressing in a single cell a ic HLA-
A/H—2K protein from a nucleotide construct, wherein the nucleotide construct ses a
cDNA sequence that encodes an a1, a2, and a3 domain of an HLA—A protein and a
transmembrane and cytoplasmic domain of a non-human H-2K protein, e.g., mouse H-2K
protein. In one ment, the nucleotide construct is a viral vector; in a specific
embodiment, the viral vector is a lentiviral . in one embodiment, the cell is selected
from a CHO, C08, 293, HeLa, and a retinal cell expressing a viral nucleic acid sequence
(e.g., a PERC.6TM cell).
In one aspect, a cell that ses a chimeric human HLA Class l/non—human
MHC l protein (e.g., HLA—A/H-2K protein) is ed. in one embodiment, the cell
comprises an expression vector comprising a chimeric MHC class I gene, wherein the
chimeric MHC class I gene comprises a sequence of a human HLA-A gene fused in
operable linkage with a sequence of a non-human H-2K gene, e.g., mouse H-2K gene. in
one embodiment, the sequence of the human HLA-A gene comprises the exons that encode
a1, a2 and 03 domains of an HLA-A protein. In one embodiment, the sequence of the non—
human H—2K gene comprises the exons that encode transmembrane and cytoplasmic
domains of an H—2K protein. In one embodiment, the cell is selected from CHO, COS, 293,
HeLa, and a retinal cell expresSing a viral nucleic acid sequence (e.g., a TM cell).
A chimeric MHC class I molecule made by a non-human animal as described
herein is also provided, wherein the chimeric MHC class I molecule comprises a1, a2, and
(13 domains from a human HLA-A protein and transmembrane and cytoplasmic domains
from a man, e.g., mouse, H-2K protein. The chimeric MHC l poiypeptide described
herein maybe detected by anti—HLA—A antibodies. Thus, a cell displaying chimeric
non—human MHC l polypeptide may be detected and/or ed using anti—HLA—A
antibody. in some instances, the chimeric MHC l polypeptide described herein maybe
detected by an anti—HLA—A2 antibody.
Although the following Examples describe a genetically engineered animal whose
genome comprises a replacement of a nucleotide sequence encoding an extracellular
domain of mouse H-2K polypeptide with the sequence ng an extraceiiular domain of a
human HLA-A at the endogenous mouse H-2K locus, one skilled in the art would understand
that a similar strategy may be used to replace other mouse MHC | loci (H-2D, H—2L, etc.)
with their corresponding human HLA loci (HLA-B, HLA-C, etc). Thus, a non-human animal
comprising in its genome a nucleotide sequence encoding a chimeric human/non-human
MHC l polypeptide n a human portion of the ptide is derived from another HLA
class l n is also provided. The replacement of multiple MHC l loci is also
contemplated.
Genetically Modified [32 Microglobulin Animals
The invention generally provides genetically modified non—human animals that
se in their genome a nucleotide sequence encoding a human or humanized [52
microglobulin polypeptide; thus, the animals s a human or humanized [32
microglobulin polypeptide.
02 microglobulin or the light chain of the MHC class l complex (also abbreviated
“(32M”) is a small (12 kDa) non-glycosylated protein, that functions primarily to stabilize the
MHC l or chain. The human [32 lobulin gene encodes a protein of 119 amino acids,
with 20 N—terminal amino acids encoding a leader sequence. The mature protein comprises
99 amino acids. The gene contains 4 exons, with the first exon containing the 5’
untranslated region, the entire leader ce and the first two amino acids of the mature
polypeptide; the second exon encoding the majority of the mature protein; the third exon
encoding the last four amino acids of the mature protein and a stop codon; and the fourth
exon ning the 3’ non-translated region. Gussow et al. (1987) The BZ-Microglobulin
Gene. Primary Structure and Definition of the Transcriptional Unit, J. lmmunol. 139:3131—38.
$2 lobulin is non—covalently associated with MHC l. Unbound [32 microglobulin is
found in body fluids, such as plasma, and is carried to the kidney for excretion. Kidney
dysfunction causes accumulation of [32 microglobulin, which can be pathogenic (e.g.,
is Related Amyloidosis); the accumulated protein forms filamentous fibrils resembling
amyloid plaques in joints and connective tissues.
in addition to Dialysis Related Amyloidosis, [32 microglobulin has been implicated
in a number of other ers. Elevated levels of {32 microglobulin were detected in
lymphocytic malignancies, e.g., dgkin’s lymphoma and multiple myeloma. See, e.g.,
Shi et al. (2009) (32 Microglobulin: Emerging as a Promising Cancer Therapeutic Target,
Drug Discovery Today 30. Some other malignancies with elevated levels of [32
lobulin include breast cancer, prostate , lung cancer, renal cancer,
gastrointestinal and nasopharyngeal cancers. Overexpression of [32 microglobulin has been
WO 63346
suggested to have tumor growth promoting effects. Id. It has also been recently shown that
[32 microglobulin drives epithelial to mesenchymal transition, promoting cancer bone and soft
tissue metastasis in breast, prostate, lung and renal cancers. Josson et al. (2011) [32
microglobulin lnduces ial to Mesenchymal Transition and Confers Cancer Lethality and
Bone Metastasis in Human Cancer Cells. Cancer Res. 71(7): 1-11. [32 microglobulin
interacts with a non-classical MHC | member, hemochromatosis (HFE) n, and with the
transferrin receptor, and modulates iron homeostasis. Id. Involvement of B2 microglobulin
in other hallmarks of malignancy (self—renewal, angiogenesis enhancement, resistance to
treatment) is widely documented in the art.
] Mice deficient in 62 microglobulin have been reported. See, Koller et al. (1990)
Normal development of mice deficient in (32m, MHC class I proteins, and CD8+ T cells,
Science 248: 1227-1230. As reported in Koller et al., these mice appeared healthy,
however, MHC class l expression was not detected. Further, most T cell populations
appeared normal in some tissues, while a marked decrease of CD8+ T cells was ed
in others. This purported lack of MHC l sion disagrees with previous results obtained
by Allen et al. ((1986) [32 microglobulin Is Not Required for Cell Surface Expression of the
Murine Class I ompatibility n H-2Db or of a Truncated H-ZDb, Proc. Natl. Acad.
Sci. USA 83:7447-7451). Allen et al. reported that (32 microglobulin was not absolutely
required for cell surface expression of all MHC l complexes, because cells lacking (32
microglobulin were able to express H—2Db. However, the function of H-2Db' in these cells
was presumably compromised, and mation of H-2Db‘was ent from the native
protein, which explains the inability of Koller and colleagues to detect this protein using
antibodies t native H-2Db. However, cells lacking [32 microglobulin can reportedly
present endogenous antigen to CD8+ T cells ding exogenous CD8+ T cells from
normal mice), and 132 microglobulin is reportedly not required in order to develop high levels
of H-2d MHC class l-restricted 008+ CTLs in response to antigen challenge in mice,
although it is required in order to sustain an effective immune response. Quinn et al. (1997)
Specific, CD8+ Major Histocompatibility Complex Class l—Restricted Cytotoxic T
cytes in Lymphocytic Choriomeningitis Virus-Infected BZ—Microglobulin-Deficient
Mice, J. Virol. 71 :8392-8396. It is of note that the ability to generate high levels of such T
cells in the absence of (32 microglobulin is reportedly limited to an H-2GI MHC class I-
cted response. 52 microglobulin deficient mice have been reported to have a host of
dramatic characteristics, such as, for example, an increased susceptibility to some tic
diseases, an increased susceptibility to hepatitis infections, a deficiency in iron metabolism,
and an impaired breeding phenotype. Cooper et al. (2007) An impaired breeding phenotype
in mice with a genetic on of Beta—2 microglobulin and diminished MHC class i
expression: Role in reproductive fitness, Biol. Reprod. 77:274-279.
Mice that express human [32 microglobulin as well as human HLA class i
molecules (i.e., ) on a randomly inserted transgene have been ed.
Chamberlain et al. (1988) Tissue-specific and cell surface expression of human major
histocompatibility complex class I heavy (HLA-B7) and light ([32-microglobulin) chain genes
in transgenic mice, Proc. Natl. Acad. Sci. USA 85:7690—7694. The expression of human
HLA class l was consistent with that of endogenous class l with a marked decrease in the
liver. Id. The expression of human [32 microglobulin was also consistent with the
endogenous [32 microglobulin, while expression of the human HLA class I molecule was
increased 10— to 17—fold in double transgenic mice. Id. However, the s did not attempt
a replacement of a mouse endogenous [32 microglobulin locus with a human [32
lobulin locus.
ore, disclosed herein is a genetically ered non—human animal (e.g.,
a rodent, e.g., a mouse or a rat) whose genome comprises a nucleotide sequence encoding
a human or humanized [32 microglobulin polypeptide. In one aspect, the animal does not
express an endogenous non-human [32 microglobulin from an endogenous non-human [32
microglobulin locus. in some embodiments, the nucleotide sequence encodes a [32
microglobulin polypeptide that is partially human and partially non—human, e.g., it contains
some amino acids that correspond to human and some amino acids that correspond to non-
human [32 microglobulin. in one aspect, the non-human animal does not express an
endogenous non-human [32 lobulin polypeptide from an endogenous non-human
locus, and only expresses the human or humanized [32 microglobulin ptide. in one
example, the non-human animal does not express a complete endogenous man [32
microglobulin polypeptide but only expresses a portion of a non-human endogenous [32
microglobulin polypeptide from an endogenous [32 lobulin locus. Thus, in various
embodiments, the animal does not express a functional non-human [32 microglobulin
polypeptide from an endogenous non—human [32 microglobulin locus. in a specific aspect,
the nucleotide sequence encoding the human or humanized [32 microglobulin is located at
an endogenous non—human [32 microglobulin locus. in one aspect, the animal comprises
two copies of [32 microglobulin locus comprising a nucleotide ce encoding a human
or humanized [32 microglobulin polypeptide. In another aspect, the animal comprises one
copy of [32 microglobulin locus comprising a nucleotide sequence encoding a human or
zed [32 microglobulin polypeptide. Thus, the animal may be homozygous or
heterozygous for [32 microglobulin locus comprising a nucleotide sequence that encodes a
human or humanized [32 microglobulin polypeptide. The nucleotide sequence of the human
or humanized B2 lobulin may be d from a collection of [32 microglobulin
sequences that are naturally found in human populations. in various embodiments, the
genetically engineered non-human animal of the invention comprises in its germline a
nucleotide sequence encoding a human or humanized [32 microglobulin. In one
embodiment, a nucleotide sequence encoding a human or humanized [32 microglobulin
polypeptide comprises a nucleotide sequence encoding a polypeptide comprising a human
[32 microglobulin amino acid sequence. in one embodiment, the polypeptide is capable of
binding to an MHC l protein.
The tide sequence encoding the human or zed [32 microglobulin
polypeptide may comprise nucleic acid residues corresponding to the entire human [32
microglobulin gene. Alternatively, the nucleotide sequence may comprise nucleic acid
residues encoding amino acid sequence set forth in amino acids 21-119 of a human [32
microglobulin n (i.e., amino acid residues ponding to the mature human [32
microglobulin). in an alternative embodiment, the nucleotide sequence may comprise
nucleic acid residues encoding amino acid sequence set forth in amino acids 23-115 of a
human [32 microglobulin protein, for example, amino acid sequence set forth in amino acids
23—119 of a human [32 microglobulin protein. The nucleic and amino acid ces of
human [32 microglobulin are described in Gussow et al., supra, incorporated herein by
reference.
Thus, the human or humanized [32 lobulin polypeptide may comprise
amino acid ce set forth in amino acids 23—1 15 of a human [32 lobulin
polypeptide, e.g., amino acid sequence set forth in amino acids 23-119 of a human [32
microglobulin polypeptide, e.g., amino acid ce set forth in amino acids 21-119 of a
human [32 microglobulin polypeptide. Alternatively, the human [32 microglobulin may
se amino acids 1—1 19 of a human [32 lobulin polypeptide.
in some embodiments, the nucleotide sequence encoding a human or humanized
[32 microglobulin comprises a nucleotide sequence set forth in exon 2 to exon 4 of a human
[32 microglobulin gene. Alternatively, the nucleotide sequence comprises nucleotide
sequences set forth in exons 2, 3, and 4 of a human [32 microglobulin gene. in this
embodiment, the nucleotide sequences set forth in exons 2, 3, and 4 are operably linked to
allow for normal transcription and ation of the gene. Thus, in one embodiment, the
human sequence comprises a nucleotide sequence corresponding to exon 2 to exon 4 of a
human [32 microglobulin gene. in a specific embodiment, the human sequence comprises a
nucleotide sequence corresponding to exon 2 to about 267 bp after exon 4 of a human [32
lobulin gene. ln a specific embodiment, the human sequence comprises about 2.8 kb
of a human [32 microglobulin gene.
] Thus, the human or humanized [32 microglobulin polypeptide may be encoded by
a nucleotide sequence comprising nucleotide sequence set forth in exon 2 to exon 4 of a
human [32 microglobulin, e.g., nucleotide sequence corresponding to exon 2 to exon 4 of a
human [32 microglobulin gene. Alternatively, the polypeptide may be encoded by a
nucleotide sequence comprising nucleotide sequences set forth in exons 2, 3, and 4 of a
human [32 microglobulin gene. In a specific embodiment, the human or humanized [32
microglobulin polypeptide is encoded by a nucleotide sequence ponding to exon 2 to
about 267 bp after exon 4 of a human [32 microglobulin gene. ln another specific
embodiment, the human or humanized polypeptide is encoded by a nucleotide sequence
comprising about 2.8 kb of a human [32 lobulin gene. As exon 4 of the [32
microglobulin gene contains the 5’ untranslated region, the human or humanized polypeptide
may be encoded by a nucleotide sequence sing exons 2 and 3 of the 82
microglobulin gene.
] It would be understood by those of ordinary skill in the art that although ic
nucleic acid and amino acid sequences to generate genetically engineered animals are
described in the present examples, sequences of one or more conservative or non-
conservative amino acid substitutions, or sequences differing from those described herein
due to the degeneracy of the genetic code, are also provided.
] Therefore, a non-human animal that expresses a human [32 microglobulin
sequence is ed, wherein the [32 microglobulin sequence is at least about 85%, 90%,
95%, 96%, 97%, 98%, or 99% identical to a human [32 microglobulin sequence. In a specific
embodiment, the [32 microglobulin sequence is at least about 90%, 95%, 96%, 97%, 98%, or
99% identical to the human [32 microglobulin sequence described in the Examples. ln one
embodiment, the human [32 lobulin sequence comprises one or more conservative
substitutions. In one embodiment, the human [32 microglobulin sequence comprises one or
more non-conservative tutions.
In addition, provided are non-human animals wherein the nucleotide ce
encoding a human or humanized [32 microglobulin protein also comprises a nucleotide
sequence set forth in exon 1 of a non—human [32 microglobulin gene. Thus, in a specific
ment, the non-human animal comprises in its genome a nucleotide sequence
encoding a human or humanized 82 microglobulin wherein the nucleotide sequence
WO 63346
comprises exon 1 of a non-human B2 microglobulin and exons 2, 3, and 4 of a human [32
microglobulin gene. Thus, the human or zed [52 microglobulin polypeptide is
encoded by exon 1 of a non-human [32 microglobulin gene and exons 2, 3, and 4 of a human
[32 microglobulin gene (e.g., exons 2 and 3 of a human |32 microglobulin gene).
Similarly to a non-human animal sing a tide sequence encoding a
chimeric human/non-human MHC l polypeptide, the non-human animal comprising a
nucleotide sequence encoding a human or humanized B2 microglobulin may be selected
from a group consisting of a mouse, rat, rabbit, pig, bovine (e.g., cow, bull, buffalo), deer,
sheep, goat, chicken, cat, dog, ferret, e (e.g., marmoset, rhesus monkey). In some
ments of the invention, the non-human animal is a . In a specific
embodiment, the non-human animal is a murine, e.g., a rodent (e.g., a mouse or a rat). In
one ment, the animal is a mouse.
Thus, in some aspects, a genetically engineered mouse is provided, wherein the
mouse comprises a nucleotide sequence encoding a human or a humanized I32
lobulin polypeptide as described herein. A genetically engineered mouse is provided,
wherein the mouse comprises at its endogenous [52 microglobulin locus a nucleotide
ce encoding a human or humanized [32 microglobulin polypeptide (e.g., a human or
substantially human [32 lobulin polypeptide). In some embodiments, the mouse does
not express an endogenous [32 microglobulin polypeptide (e.g., a functional endogenous [32
microglobulin polypeptide) from an endogenous I32 microglobulin locus. In some
embodiments, the genetically engineered mouse ses a tide sequence
comprising exon 1 of a mouse [32 microglobulin gene and exons 2, 3, and 4 of a human [32
microglobulin gene. In some embodiments, the mouse expresses the human or humanized
(32 microglobulin ptide.
In one aspect, a modified non—human [32 microglobulin locus is provided that
comprises a heterologous {32 microglobulin sequence. In one embodiment, the
heterologous [52 microglobulin ce is a human or a humanized sequence.
In one embodiment, the modified locus is a rodent locus. In a specific
embodiment, the rodent locus is selected from a mouse or rat locus. In one embodiment,
the non-human locus is modified with at least one human {32 microglobulin coding sequence.
In one embodiment, the heterologous [32 microglobulin sequence is operably
linked to endogenous regulatory elements, e.g., endogenous promoter and/or expression
control sequence. In a specific embodiment, the heterologous I32 microglobulin sequence is
WO 63346
a human sequence and the human sequence is operably linked to an endogenous promoter
and/or expression control ce.
in one aspect, a modified non—human [32 lobulin locus is provided that
comprises a human sequence operably linked to an endogenous promoter and/or
expression control sequence.
In various aspects, the human or humanized [32 microglobulin expressed by a
cally modified non—human animal, or cells, embryos, or tissues derived from a non-
human , preserves all the functional aspects of the endogenous and/or human [32
microglobulin. For e, it is preferred that the human or humanized [32 microglobulin
binds the on chain of MHC l polypeptide (e.g., endogenous non—human or human MHC l
polypeptide). The human or humanized [32 microglobulin polypeptide may bind, recruit or
othen/vise associate with any other les, e.g., receptor, anchor or signaling molecules
that associate with endogenous non-human and/or human [32 microglobulin (e.g., HFE, etc).
] in addition to genetically modified animals (e.g., rodents, e.g., mice or rats), also
provided is a tissue or cell, wherein the tissue or cell is derived from a non—human animal as
described herein, and ses a heterologous [32 microglobulin gene or [32 microglobulin
sequence, i.e., nucleotide and/or amino acid sequence. In one embodiment, the
heterologous [32 microglobulin gene or 62 microglobulin sequence is a human or humanized
[32 microglobulin gene or human or humanized [32 microglobulin sequence. Preferably, the
cell is a nucleated cell. The cell may be any cell known to express MHC l complex, e.g., an
antigen presenting cell. The human or humanized [32 lobulin polypeptide expressed
by said cell may interact with endogenous non-human MHC l (e.g., rodent MHC l), to form a
functional MHC l complex. The resultant MHC l complex may be capable of interacting with
a T cell, e.g., a cytotoxic T cell. Thus, also provided is an in vitro complex of a cell from a
non-human animal as described herein and a T cell.
Also provided are man cells that comprise human or humanized [32
microglobulin gene or sequence, and an additional human or humanized sequence, e.g.,
chimeric MHC l ptide presently disclosed. In such an instance, the human or
humanized [32 microglobulin ptide may interact with, e.g., a ic human/non-
human MHC l polypeptide, and a functional MHC l x may be formed. In some
aspects, such complex is capable of interacting with a TCR on a T cell, e.g., a human or a
non-human T cell. Thus, also provided in an in vitro complex of a cell from a non-human
animal as described herein and a human or a non-human T cell.
Another aspect of the disclosure is a rodent embryo (e.g., a mouse or a rat
embryo) comprising a heterologous {32 microglobulin gene or [32 microglobulin sequence as
described herein. In one embodiment, the embryo ses an E8 donor cell that
comprises the heterologous [32 microglobulin gene or [32 microglobulin sequence, and host
embryo cells. The heterologous [32 microglobulin gene or {52 microglobulin sequence is a
human or humanized [32 microglobulin gene or {32 microglobulin sequence.
This invention also encompasses a non-human cell comprising a chromosome or
fragment thereof of a non-human animal as bed herein (e.g., n the chromosome
or nt thereof comprises a tide sequence encoding a human or humanized [32
microglobulin polypeptide). The non-human cell may comprise a nucleus of a non-human
animal as described . in one embodiment, the non—human cell comprises the
chromosome or fragment thereof as the result of a nuclear transfer.
In one aspect, a non—human induced pluripotent cell comprising a logous
[32 microglobulin gene or {32 microglobulin sequence is provided. In one embodiment, the
induced pluripotent cell is derived from a non—human animal as described herein. In one
embodiment, the heterologous [32 microglobulin gene or [32 microglobulin sequence is a
human or humanized gene or sequence.
Also provided is a hybridoma or quadroma, derived from a cell of a non-human
animal as described herein. ln one embodiment, the non-human animal is a mouse or rat.
The disclosure also provides methods for making a genetically engineered non—
human animal (e.g., a genetically engineered rodent, e.g., a mouse or a rat) described
herein. The methods result in an animal whose genome ses a tide sequence
encoding a human or zed [52 microglobulin polypeptide. in one aspect, the methods
result in a genetically engineered mouse, whose genome comprises at an endogenous 02
lobulin locus a nucleotide sequence ng a human or humanized [32
microglobulin polypeptide. In some instances, the mouse does not express a functional
mouse [32 microglobulin from an endogenous mouse [32 lobulin locus. in some
aspects, the methods utilize a targeting construct made using VELOCIGENE® technology,
introducing the uct into ES cells, and introducing targeted ES cell clones into a mouse
embryo using VELOCIMOUSE® technology, as described in the Examples. in one
embodiment, the ES cells are mix of 129 and C57BL/6 mouse strains; in another
embodiment, the ES cells are a mix of BALB/c and 129 mouse strains.
Also provided is a nucleotide construct used for generating genetically
engineered non-human animals. The nucleotide construct may comprise: 5’ and 3’ non-
human homology arms, a human DNA fragment sing human B2 microglobulin
sequences, and a ion cassette flanked by recombination sites. in one embodiment,
the human DNA fragment is a genomic fragment that comprises both introns and exons of a
human B2 microglobulin gene. in one embodiment, the non-human homology arms are
homologous to a non-human B2 microglobulin locus. The genomic fragment may comprise
exons 2, 3, and 4 of the human B2 microglobulin gene. in one instance, the genomic
fragment comprises, from 5’ to 3’: exon 2, , exon 3, intron, and exon 4, all of human B2
microglobulin sequence. The selection cassette may be located anywhere in the construct
outside the B2 lobulin coding region, e.g., it may be located 3’ of exon 4 of the human
B2 microglobulin. The 5’ and 3’ non-human homology arms may comprise genomic
sequence 5’ and 3’ of endogenous non-human B2 microglobulin gene, respectively. in
another embodiment, the 5' and 3’ non-human homology arms comprise genomic sequence
’ of exon 2 and 3’ of exon 4 of endogenous non—human gene, respectively.
Another aspect of the invention relates to a method of modifying a B2
microglobulin locus of a man animal (e.g., a rodent, e.g., a mouse or a rat) to express
a human or humanized B2 microglobulin polypeptide described herein. One method of
modifying a B2 microglobulin locus of a mouse to s a human or humanized B2
microglobulin polypeptide ses ing at an endogenous B2 microglobulin locus a
nucleotide sequence encoding a mouse B2 microglobulin with a nucleotide sequence
encoding the human or humanized B2 microglobulin polypeptide. In one embodiment of
such method, the mouse does not express a onal B2 microglobulin polypeptide from an
endogenous mouse B2 lobulin locus. In some specific embodiments, the nucleotide
sequence encoding the human or humanized B2 microglobulin ptide comprises
nucleotide sequence set forth in exons 2 to 4 of the human B2 microglobulin gene. In other
embodiments, the nucleotide sequence encoding the human or humanized B2 microglobulin
polypeptide comprises tide sequences set forth in exons 2, 3, and 4 of the human B2
microglobulin gene.
Genetically Modified MHC | I B2 lobulin Animals
In various embodiments, the invention generally provides genetically modified
non-human animals that se in their genome nucleotide sequences encoding both
human or humanized MHC l and B2 microglobulin polypeptides; thus, the animals s
both human or humanized MHC l and B2 microglobulin polypeptides.
Functional differences arise in the use of mixed human/non-human system
components. HLA class l binds B2 microglobulin tighterthan mouse class I. Bernabeu
(1984) fiZ—microgobulin from serum ates with MHC class I antigens on the surface of
cultured cells, Nature 3082642-645. Attempts to abrogate functional differences are reflected
in the construction of particular humanized MHC mice. H-2 class I and class 2 knockout
mice (in a mouse {32 microglobulin KO background) that express a randomly integrated
human HLA—A2.1/HLA—DR1 chimeric transgene having an at and a2 of human HLA—A2.1,
and Q3 of mouse H—2Db, attached at its N-terminal via a linker to the C-terminus of human
fiZ-microglobulin have been developed. See, e.g., Pajot et al. (2004) A mouse model of
human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H—2 class I-/class Il-
ut mice, Eur. J. lmmunol. 0-3069. These mice reportedly generate antigen-
specific antibody and CTL responses against hepatitis B virus, whereas mice merely
transgenic for HLA—A2.1 or H-2 class l/class ll knockout mice do not. The deficiency of mice
that are merely transgenic for the genes presumably stems from the ability of such mice to
employ endogenous class I and/or class ll genes to circumvent any transgene, an option not
available to MHC knockout mice. However, the mice may express at least H-2Db,
presumably due to breedings into the mouse [32 microglobulin knockout mouse background
(see, Pajot et al., supra; which apparently comprised an intact endogenous class l and class
II locus).
Cell surface sion of the chimeric fusion with human [32 microglobulin is
reportedly lower than endogenous MHC expression, but survivability/rate of NK killing is not
reported, nor is the rate of NK self—killing. Pajot et al., supra. Some improvement in CD8+ T
cell numbers was ed over MHC class l-deficient croglobulin knockout mice (2-
3% of total splenocytes, vs. 0.64% in the (32 KO mice). However, T cell variable region
usage exhibited altered profiles for BV 5.1, BV 5.2, and BV 11 gene segments. Both CD8+
and CD4+ T cell responses were reportedly restricted to the appropriate tis B n
used to immunize the mice, although at least two mice killed cells bearing either of the
antigens, where the mice were immunized with only one antigen, which might be due to a
lack of NK cell tion or lack of NK cell selectivity.
] As mentioned above, mice transgenic for both human MHC l and human 62
microglobulin comprise a nucleotide sequence encoding a chimeric MHC l/132 microglobulin
protein, wherein the MHC l and [32 lobulin portions are ned within a single
polypeptide chain, resulting in MHC l a chain and [32 microglobulin being covalently linked to
each other and thereby tethered at the cell surface. A mouse which comprises in its
genome two independent nucleotide sequences, one encoding a human or humanized MHC
l polypeptide and the other ng a human or humanized [32 microglobulin polypeptide is
ed. The mouse provided herein would express an MHC l complex that more closely
2012/062042
resembles an MHC l complex t in nature, wherein MHC l or chain and {32
microglobulin are provided on two separate polypeptide chains with [32 microglobulin non-
covalently associating with the MHC l a chain.
Thus, the present disclosure es a non—human animal comprising in its
genome: a first nucleotide ce encoding a human or humanized MHC l polypeptide,
and a second nucleotide sequence encoding a human or humanized [32 microglobulin
polypeptide. In one aspect, provided is a non-human animal comprising in its genome: (a) a
first nucleotide sequence ng a chimeric human/non-human MHC l polypeptide,
wherein the human portion of the chimeric polypeptide comprises a e binding domain
or an ellular domain ofa human MHC l (e.g., HLA-A, HLA—B, or HLA—C; e.g., HLA—A2),
and (b) a second nucleotide sequence encoding a human or humanized [32 microglobulin
polypeptide.
The first nucleotide sequence may be located at an endogenous non-human
MHC l locus such that the animal comprises in its genome a replacement at the MHC l locus
of all or a portion of endogenous MHC l gene (e.g., a portion encoding a peptide binding
domain or an extracellular domain) with the corresponding human MHC l sequence. Thus,
the animal may comprise at an endogenous MHC l locus a tide sequence ng
an extracellular domain ofa human MHC l (e.g., HLA-A, HLA—B, or HLA-C; e.g., HLA-AZ)
and transmembrane and cytoplasmic domains of endogenous non-human MHC l (e.g., H-
2K, H-2D, etc, e.g., H-2Kb). in one aspect, the animal is a mouse, and the first nucleotide
sequence comprises a nucleotide ce encoding an extracellular domain of a human
HLA—A2 (e.g., HLA—A2.1) and embrane and cytoplasmic domains of a mouse H—2K
(e.g., H-2Kb).
The second nucleotide sequence may be located at an endogenous non—human
[32 microglobulin locus such that the animal comprises in its genome a replacement at the [32
microglobulin locus of all or a portion of endogenous [32 microglobulin gene with the
corresponding human [32 microglobulin sequence. The second nucleotide sequence may
comprise a nucleotide sequence set forth in exon 2 to exon 4 of a human {32 microglobulin
gene. Alternatively, the second nucleotide sequence may comprise nucleotide sequences
set forth in exons 2, 3, and 4 of a human {32 microglobulin gene. in this embodiment,
nucleotide sequences are ly linked to each other. The second tide sequence
may further comprise the sequence of exon 1 of a non—human [32 microglobulin gene.
in one aspect, the animal does not express a functional MHC l from an
nous non—human MHC l locus (e.g., does not express either a peptide binding
domain or an ellular domain of the endogenous MHC l), and the animal does not
express a functional (32 microglobulin polypeptide from an endogenous non-human [32
microglobulin locus. in some aspects, the animal is homozygous for both an MHC i locus
comprising a nucleotide sequence encoding a chimeric human/non—human MHC I
ptide and a [32 microglobulin locus sing a nucleotide sequence encoding a
human or humanized {32 microglobulin. In other aspects, the animal is heterozygous for
both an MHC I locus comprising a nucleotide sequence encoding a chimeric human/non-
human MHC l polypeptide and a [32 microglobulin locus comprising a nucleotide sequence
encoding a human or humanized [32 microglobulin.
Preferably, the first and the second nucleotide ces are operably linked to
endogenous expression control elements (e.g., promoters, enhancers, silencers, etc).
Various other embodiments of the first and second nucleotide sequences (and
the polypeptides they encode) encompassed herein may be readily understood from the
embodiments described hout the specification, e.g., those described in the sections
related to genetically engineered MHC | animals and genetically engineered [32
microglobulin animals.
in one aspect, the disclosure provides a mouse sing in its genome (a) a
first nucleotide sequence encoding a chimeric human/mouse MHC | polypeptide
(specifically, HLA—AZ/H-ZK polypeptide), wherein the human portion of the chimeric
ptide comprises an extracellular domain of a human HLA-AZ and the mouse portion
comprises transmembrane and cytoplasmic s of a mouse H-2K, and (b) a second
nucleotide sequence encoding a human or zed [32 microglobulin polypeptide (e.g.,
wherein the tide ce comprises a nucleotide sequence set forth in exon 2 to
exon 4 of the human [32 microglobulin gene or nucieotide sequences set forth in exon 2, 3,
and 4 of the human [32 microglobulin gene), wherein the first nucleotide sequence is d
at an endogenous H—2K locus, and the second sequence is located at an endogenous [32
microglobulin locus. In one embodiment, the mouse does not express functional H—2K and
mouse [32 microglobulin polypeptides from their respective endogenous loci. In one
embodiment, the mouse expresses both the chimeric human/mouse MHC i polypeptide and
the human or humanized [52 microglobulin polypeptide.
As shown in the ing Examples, animals genetically engineered to co-
express both the human or humanized MHC l and [32 microglobulin displayed sed
expression of chimeric MHC class I on celi surface in comparison to animals humanized for
MHC 1 alone. in some ments, co-expression of human or humanized MHC i and [32
microglobulin ses cell surface expression of human or humanized MHC i by more than
about 10%, e.g., more than about 20%, e.g., about 50% or more, e.g., about 70%, over the
expression of human or humanized MHC l in the absence of human or humanized {32
microglobulin.
The disclosure also provides a method of making genetically engineered nonhuman
s (e.g., rodents, e.g., rats or mice) whose genome comprises a first and a
second nucleotide sequence as bed herein. The method generally comprises
generating a first genetically engineered non-human animal whose genome ses a first
nucleotide sequence described herein (i.e., a human or humanized MHC l sequence),
generating a second genetically engineered non—human animal whose genome comprises a
second nucleotide sequence described herein (i.e., a human or humanized [32 microglobulin
sequence), and breeding the first and the second animal to obtain progeny whose genome
contains both nucleotide sequences. in one embodiment, the first and the second animal
are heterozygous for the first and the second nucleotide sequence, respectively. in one
embodiment, the first and the second animal are gous for the first and the second
tide sequence, respectively. In one embodiment, the first and second animals are
generated through replacement of endogenous man loci with the first and the second
nucleotide sequences, respectively. in one , the first and the second s are
generated through ation of constructs generated via VELOClGENE® technology, and
introducing targeted ES cell clones bearing such constructs into an embryo (e.g., a rodent
embryo, e.g., a mouse or a rat embryo) via the VELOClMOUSE® method.
Use of Genetically Modified Animals
In various embodiments, the genetically modified non—human animals described
herein make APCs with human or humanized MHC l and/or [32 lobulin on the cell
surface and, as a result, present peptides derived from cytosolic proteins as epitopes for
CTLs in a like manner, because substantially all of the components of the complex
are human or humanized. The genetically modified non-human animals of the invention can
be used to study the on of a human immune system in the zed animal; for
fication of antigens and antigen epitopes that elicit immune response (e.g., T cell
epitopes, e.g., unique human cancer epitopes), e.g., for use in vaccine development; for
identification of high affinity T cells to human pathogens or cancer antigens (i.e., T cells that
bind to antigen in the context of human MHC l complex with high avidity), e.g., for use in
adaptive T cell therapy; for evaluation of vaccine candidates and other vaccine strategies;
for studying human autoimmunity; for studying human infectious diseases; and otherwise for
ng better therapeutic strategies based on human MHC expression.
The MHC l complex binds peptides and presents them on cell surface. Once
presented on the surface in the context of such a complex, the peptides are recognizable by
T cells. For example, when the peptide is derived from a pathogen or other antigen of
interest (e.g., a tumor antigen), T cell recognition can result in T cell activation, macrophage
killing of cells bearing the presented peptide sequence, and B cell activation of antibodies
that bind the presented sequence.
T cells interact with cells expressing MHC l complex through the peptide—bound
MHC class i ectodomain and the T cell‘s CD8 ectodomain. CD8+ T cells that encounter
APC's that have suitable antigens bound to the MHC class i molecule will become cytotoxic
T cells. Thus, antigens that in the context of MHC class l bind with high avidity to a T cell
receptor are potentially important in the development of treatments for human pathologies.
However, tation of antigens in the context of mouse MHC | is only somewhat relevant
to human disease, since human and mouse MHC compiexes recognize antigens differently,
e.g., a mouse MHC l may not recognize the same antigens or may present different epitopes
than a human MHC l. Thus, the most nt data for human pathologies is obtained
through studying the presentation of antigen epitopes by human MHC I.
Thus, in various ments, the cally engineered s of the present
invention are useful, among other things, for evaluating the capacity of an n to te
an immune response in a human, and for generating a diversity of antigens and identifying a
specific n that may be used in human vaccine development.
In one aspect, a method for determining antigenicity in a human of a peptide
ce is provided, comprising exposing a genetically modified non—human animal as
described herein to a molecule comprising the peptide sequence, allowing the non—human
animal to mount an immune response, and detecting in the non-human animal a cell that
binds a sequence of the peptide ted by a chimeric non-human MHC l, or a
humanized MHC t complex (comprising a chimeric human/non—human MHC l and a human
or humanized [32 microglobulin) as described herein.
In one aspect, a method for determining r a peptide will provoke a cellular
immune response in a human is provided, sing exposing a genetically modified non-
human animal as described herein to the e, allowing the non—human animal to mount
an immune response, and detecting in the non-human animal a cell that binds a sequence of
the peptide by a chimeric human/non-human MHC class i molecule as described . In
one embodiment, the non-human animal following exposure comprises an MHC class l-
restricted CD8+ xic T lymphocyte (CTL) that binds the peptide. in one embodiment,
the CTL kills a cell bearing the peptide.
In one aspect, a method for identifying a human CTL epitope is provided,
comprising exposing a non-human animal as described herein to an antigen comprising a
putative CTL epitope, allowing the non-human animal to mount an immune response,
isolating from the non-human animal an MHC class I-restricted CD8+ CTL that binds the
epitope, and identifying the epitope bound by the MHC class I-restricted CD8+ CTL.
In one aspect, a method is provided for identifying an HLA class I—restricted
peptide whose presentation by a human cell and binding by a human lymphocyte (e.g.,
human T cell) will result in cytotoxicity of the peptide—bearing cell, sing exposing a
non-human animal (or MHC class I-expressing cell thereof) as described herein to a
molecule sing a peptide of interest, isolating a cell of the non-human animal that
expresses a chimeric human/non—human class I le that binds the peptide of interest,
exposing the cell to a human lymphocyte that is capable of conducting HLA class I-restricted
cytotoxicity, and measuring peptide-induced cytotoxicity.
In one aspect, a method is provided for fying an n that generates a
cytotoxic T cell response in a human, comprising exposing a putative antigen to a mouse as
described herein, allowing the mouse to generate an immune response, and identifying the
antigen bound by the HLA-A-restricted molecule.
In one embodiment, the antigen comprises a bacterial or viral surface or
envelope n. In one embodiment, the antigen comprises an antigen on the surface of a
human tumor cell. In one embodiment, the antigen comprises a putative vaccine for use in a
human. In one embodiment, the antigen comprises a human epitope that tes
dies in a human. In another embodiment, the n comprises a human epitope that
tes high affinity CTLs that target the epitope/MHC I complex.
In one aspect, a method is provided for determining whether a putative antigen
contains an epitope that upon exposure to a human immune system will generate an HLA-A-
restricted immune response (e.g., HLA—AZ—restricted response), sing exposing a
mouse as described herein to the putative antigen and ing an antigen—specific HLA—
A—restricted (e.g., -restricted) immune response in the mouse.
In one embodiment, the putative antigen is selected from a biopharmaceutical or
fragment thereof, a non-self protein, a e antigen of a lf cell, a surface n of
a tumor cell, a surface antigen of a bacterial or yeast or fungal cell, a surface antigen or
pe protein of a virus.
In addition, the genetically engineered non-human animals described herein may
be useful for identification of T cell receptors, e.g., high-avidity T cell receptors, that
recognize an antigen of interest, e.g., a tumor or another disease antigen. The method may
comprise: exposing the non-human animal described herein to an antigen, allowing the non-
human animal to mount an immune response to the antigen, isolating from the non-human
animal a T cell comprising a T cell or that binds the n presented by a human or
zed MHC l, and determining the sequence of said T cell receptor.
in one aspect, a method for identifying a T cell or variable domain having
high affinity for a human tumor antigen is provided, comprising exposing a mouse
comprising humanized MHC l a1, a2, and a3 domains (e.g., HLA—A2 a1, a2, and a3
domains) to a human tumor antigen; allowing the mouse to generate an immune response;
and, isolating from the mouse a nucleic acid sequence encoding a T cell receptor variable
domain, wherein the T cell receptor variable domain binds the human tumor antigen with a
KB of no higher than about 1 nanomolar.
in one embodiment, the mouse further ses a replacement at the
endogenous mouse T cell receptor variable region gene locus with a plurality of
unrearranged human T cell receptor variable region gene ts, wherein the
unrearranged human T cell receptor variable region gene segments recombine to encode a
chimeric human-mouse T cell receptor gene comprising a human variable region and a
mouse constant region. in one ment, the mouse comprises a human CD8
ene, and the mouse expresses a functional human CD8 protein.
T cell receptors having high avidity to tumor antigens are useful in ased
therapeutics. T cell populations with high avidity to human tumor antigens have been
prepared by ng human T cells to HLA-A2 that has been mutated to minimize CD8
binding to the G3 t, in order to select only those T cells with extremely high avidity to
the tumor antigen (i.e., T cell clones that recognize the antigen in spite of the inability of CD8
to bind (13). See, Pittet et al. (2003) GB Domain Mutants of Peptide/MHC Class I Multimers
Allow the Selective isolation of High Avidity Tumor-Reactive CD8 T Cells, J. Immunol.
171 1849. The non-human animals, and cells of the non-human animals, are useful
for identifying es that will form a complex with human HLA class I that will bind with
high avidity to a T cell or, or activate a lymphocyte bearing a T cell receptor.
Antigen/HLA class i binding to a T cell, or activation of a T cell, can be ed
by any suitable method known in the art. Peptide—specific APC-T Cell binding and activation
are measurable. For example, T cell engagement of antigen-presenting cells that express
HLA—A2 reportedly causes P|P2 to accumulate at the immunosynapse, whereas cross-
linking MHC class i molecules does not. See, Fooksman et al. (2009) Cutting Edge:
Phosphatidylinositol 4,5—Bisphosphate Concentration at the APC Side of the immunological
Synapse is Required for Effector T Cell Function, J. lmmunol. 182:5179-5182.
Functional consequences of the interaction of a lymphocyte bearing a TCR, and
a class I—expressing APC, are also measurable and include cell killing by the lymphocyte.
For example, contact points on the a2 subunit of HLA-A2 by CD8+ CTLs reportedly
generate a signal for Fas—independent killing. —expressing Jurkat cells apoptose
when contacted (by antibodies) at epitopes on the HLA-A2 le known (from
crystallographic s) to contact CD8, without any apparent reliance on the cytoplasmic
. See, Pettersen et al. (1998) The TCR-Binding Region of the HLA Class l 02
Domain Signals Rapid Fae-Independent Cell Death: A Direct Pathway for T Cell-Mediated
Killing of Target Cells? J. lmmunol. 160:4343-4352. It has been postulated that the rapid
killing induced by HLA—A2 a2 contact with a CD8 of a CD8+ CTL may primarily be due to
this Fas-independent HLA-AZ-mediated pathway (id), as distinguished from TCR-
independent 03 domain-mediated killing—which by itself can induce apoptosis (see, Woodle
et al. (1997) Anti—human class I MHC antibodies induce apoptosis by a pathway that is
distinct from the Fas antigen-mediated pathway, J. Immunol. 158:2156—2164).
The uence of interaction between a T cell and an APC displaying a
peptide in the t of MHC I can also be measured by a T cell proliferation assay.
Alternatively, it can be determined by measuring cytokine e commonly associated with
tion of immune response. In one embodiment, IFNy ELISPOT can be used to monitor
and quantify CD8+ T cell activation.
As bed herein, CD8+ T cell activation can be hampered in the genetically
modified non-human animals described herein due to species-specific g of CD8 to
MHC I. For embodiments where a species-specific CD8 interaction is desired, a cell of a
genetically modified animal as described herein (e.g., a rodent, e.g., a mouse or a rat) is
exposed (e.g., in vitro) to a human cell, e.g., a human CD8-bearing cell, e.g., a human T cell.
In one embodiment, an MHC class I-expressing cell of a mouse as described herein is
exposed in vitro to a T cell that comprises a human CD8 and a T cell receptor. In a specific
embodiment, the T cell is a human T cell. In one embodiment, the MHC class l-expressing
cell of the mouse comprises a peptide bound to a chimeric mouse MHC l or a
humanized MHC I x (which es human [32 microglobulin), the T cell is a human
T cell, and the ability of the T cell to bind the peptide-displaying mouse cell is determined. In
one embodiment, activation of the human T cell by the peptide-displaying mouse cell is
determined. In one embodiment, an in vitro method for measuring activation of a human T
cell by the peptide-displaying cell is provided, comprising exposing a mouse or a mouse cell
as described herein to an antigen of interest, exposing a cell from said mouse or said mouse
cell mably g a peptide derived from the antigen in complex with human or
humanized MHC I) to a human T cell, and measuring activation of the human T cell. In one
embodiment, the method is used to identify a T cell epitope of a human en or a
human neopiasm. In one embodiment, the method is used to identify an epitope for a
In one embodiment, a method is provided for ining T cell activation by a
putative human therapeutic, comprising exposing a genetically modified animal as described
herein to a putative human therapeutic (or e.g., exposing a human or humanized MHC l—
expressing cell of such an animal to a peptide sequence of the putative therapeutic),
exposing a cell of the genetically modified animal that displays a human or humanized MHC
l/peptide complex to a T cell comprising a human T cell receptor and a CD8 capable of
binding the cell of the genetically modified animal, and measuring tion of the human T
cell that is d by the peptide—displaying cell of the genetically modified animal.
In various ments, a complex formed between a human or humanized
MHC class l-expressing cell from an animal as described herein is made with a T cell that
comprises a human CD8 sequence, e.g., a human T cell, or a T cell of a non-human animal
that comprises a transgene that encodes human CD8. Mice transgenic for human CD8 are
known in the art. Tishon et al. (2000) nic Mice Expressing Human HLA and CD8
Molecules Generate HLA-Restricted s Virus Cytotoxic T Lymphocytes of the Same
Specificity as Humans with Natural Measles Virus Infection, Virology 275(2):286-293; also,
LaFace et al. (1995) Human CD8 Transgene Regulation of HLA Recognition by Murine T
Cells, J. Exp. Med. 182:1315-1325.
In addition to the ability to identify antigens and antigen epitopes from human
pathogens or neoplasms, the genetically modified animals of the invention can be used to
identify autoantigens of relevance to human autoimmune diseases, e.g., type i diabetes,
le sclerosis, etc. For example, Takaki et al. ((2006) HLA-A*0201-Restricted T Cells
from Humanized NOD Mice Recognize Autoantigens of Potential Clinical Relevance to Type
1 Diabetes, J. lmmunol. 176:3257—65) describe the utility of NOD mice bearing 2
microglobulin monochain in identifying type 1 diabetes autoantigens. Also, the genetically
modified animals of the invention can be used to study various aspects of human
autoimmune disease. As some polymorphic alleles of human MHC l are known to be
associated with development of certain es, e.g., mune diseases (e.g., Graves’
disease, myasthenia gravis, psoriasis, etc; see Bakker et al. (2006) A high—resolution HLA
and SNP haplotype map for disease ation studies in the extended human MHC,
Nature Genetics 38:1166-72 and Supplementary Information and international MHC and
munity Genetics Network (2009) Mapping of multiple susceptibility ts within the
MHC region for 7 immune—mediated diseases, Proc. Natl. Acad. Sci. USA 106:18680-85,
both incorporated herein by reference), a genetically modified animal of the invention
comprising a humanized MHC l locus including such an allele may be useful as an
autoimmune disease model. In one embodiment, the disease allele is HLA-827, and the
disease is ankyiosing spondylitis or reactive arthritis; thus, in one embodiment, the animal
used for the study of these es comprises a human or humanized HLA-827.
] Other aspects of cellular immunity that involve MHC | complexes are known in
the art; therefore, genetically ered non-human animals described herein can be used
to study these aspects of immune biology. For instance, g of TCR to MHC class i is
modulated in vivo by additional factors. Leukocyte immunoglobulin—like receptor subfamily B
member (LlLRBi, or LlR-l) is expressed on MHC Class l—restricted CTLs and down;
regulates T cell stimulation by binding a specific determinant on the a3 subunit of MHC class
I molecules on APCs. Structural studies show that the binding site for LIR-1 and CD8
overlap, suggesting that inhibitory LIR-1 competes with stimulatory CD8 for binding with
MHC class I molecules. Willcox et al. (2003) l structure of HLA-A2 bound to LlR-t, a
host and viral major ompatibility complex receptor, Nature immunology 4(9):913-919;
also, Shirioshi et al. (2003) Human inhibitory receptors lg-like transcript 2 (ILT2) and lLT4
compete with CD8 for MHC class I binding and bind preferentially to HLA—G, Proc. Natl.
Acad. Sci. USA 100(15):8856—8861. LlR-1 transduces inhibitory signals through its
(intracellular) receptor tyrosine-based inhibitory motif (ITIM). In NK cells, studies
have shown that Kle (inhibitory killer cell lg-like receptors) lacking lTlMs (normally
ble of inhibition) can inhibit in the presence of LlR—1 (presumably through the LlR-1
lTlM) bound to the QB domain of an MHC class i molecule (see, Kirwin et al. (2005) Killer
Cell e Receptor-Dependent Signaling by lg—Like Transcript 2 (lLT2/CD85j/LlLRBt/LIR-
1) J. Immunol. 175:5006—5015), suggesting cooperation between LlR—l bound to MHC class
i and Kle and thus a role for HLA 0L3 domain g in modulating NK cell inhibition.
As described above, MHC molecules interact with cells that do not express a
TCR. Among these cells are NK cells. NK cells are cytotoxic lymphocytes (distinguished
from CTLs, or cytotoxic T lymphocytes) that play a central role in the cellular immune
response, and in particular innate immunity. NK cells are the first line of defense against
ng microorganisms, s, and other non-self (e.g., tumor) entities. NK cells are
activated or inhibited through surface receptors, and they s CD8 but do not express
TCRs. NK cells can interact with cells that express MHC class I, but interaction is through
the nding a3 domain rather than the TCR-binding, peptide—bearing a1 and a2
domains. A primary function of NK cells is to destroy cells that lack sufficient MHC class i
surface protein.
linking MHC class I molecules on the surface of human natural killer (NK)
cells results in intracellular tyrosine phosphorylation, migration of the MHC class I molecule
from the lmmunosynapse, and down-regulation of tumor cell killing. Rubio et al. (2004)
Cross-linking of MHC class l les on human NK cells ts NK cell function,
segregates MHC l from the NK cell synapse, and s intracellular phosphotyroslnes, J.
Leukocyte Biol. 76:116-124.
Another function of MHC class I in NK cells ls apparently to prevent self—killing.
NK cells bear both activating receptor 284 and the 2B4 ligand CD48; MHC class l appears
to bind 284 and prevent its activation by CD48. Betser-Cohen (2010) The ation of
MHC Class l Proteins with the 284 or Inhibits Self-Killing of Human NK Cells, J.
Immunol. 184:2761-2768.
Thus, the genetically engineered non-human animals described herein can be
used to study these non—TCR or L mediated ses and to design approaches for
their tion.
EXAMPLES
The invention will be further illustrated by the following nonllmiting examples.
These Examples are set forth to aid in the understanding of the invention but are not
intended to, and should not be construed to, limit its scope in any way. The Examples do not
include detailed descriptions of conventional methods that would be well known to those of
ordinary skill in the art (molecular cloning techniques, etc). Unless indicated otherwise,
parts are parts by weight, molecular weight is average molecular weight, temperature is
indicated in Celsius, and pressure is at or near atmospheric.
Example 1. Construction and Characterization of Genetically Modified HLA-A2 Mice
Example 1.1: Expression of HLA—A2/H—2K in MG87 Cells.
A viral construct ning a chimeric HLA-A2lH—2K gene ce ()
was made using rd molecular cloning techniques known to a skilled artisan in order to
analyze chimeric human/mouse MHC | expression in transfected cells.
Briefly, a chimeric human mouse H—2K viral construct was made using the
exon sequences ng the 0:1, a2 and a3 domains of the 0: chain and cloning them in
frame with the mouse coding sequences for the transmembrane and cytoplasmic domains
from the H—2K gene (, leG-HLA—AZ/HZK). As illustrated in the construct
contained an IRES-GFP reporter sequence, which allowed for determining if the construct
was able to express in cells upon transfection.
Viruses containing the chimeric construct described above were made and
propagated in human nic kidney 293 (293T) cells. 293T cells were plated on 10 cm
dishes and allowed to grow to 95% confluency. A DNA transfection mixture was prepared
with 25 pg of leG-HLA—A2/H2K, leG—human HLA—A2, or leG-humanized [32
microglobulin, and 5 pg of pMDG (envelope plasmid), 15 pg of pCL-Eco (packaging
construct without packaging signal 1P), 1 mL of Opti—MEM (lnvitrogen). Added to this 1 mL
DNA mixture was 80 pL of Lipofectamine—ZOOO (lnvitrogen) in 1 mL of Opti-MEM, which was
previously mixed together and allowed to incubate at room temperature for 5 minutes. The
Lipofectamine/DNA mixture was allowed to incubate for an additional 20 minutes at room
ature, and then was added to 10 cm dishes, and the plates were incubated at 37°C.
Media from the cells was collected after 24 hours and a fresh 10 mL of R10 (RPMI 1640 +
% FBS) media was added to the cells. This media exchange was repeated twice. After a
total of four days, the collected media was pooled, centrifuged and passed through a sterile
filter to remove ar debris.
The propagated viruses made above were used to transduce M687 (mouse
fibroblast) cells. M687 cells from a single T-75 flask were washed once with PBS. 3 mL of
0.25% Trypsin + EDTA was added to the cells and allowed to incubate at room temperature
for three s. 7 mL of D10 (high e DMEM; 10% Fetal Bovine Serum) was added
to the ceils/trypsin mixture and transferred to a 15 mL tube to centrifuge at 1300 rpm for five
minutes. After centrifuging the cells, the media was ted and the cells resuspended in
mL D10. Cells were counted and ~13.0x105 cells were placed per well in a 63—well plate.
leG-human HLA—A2 or leG-HLA—A2/H-2K either alone or with manized [32
microglobulin virus were added to the wells, with non-transduced cells as a control. Cells
were incubated at 37°C with 5% 002 for 2 days. Cells were ed for FACS analysis
(using anti—HLA-AZ antibody, clone 887.2) for HLA—A2 expression with or without {32
lobulin.
The graphs (), as well as the table izing the data obtained from
the graphs () demonstrate that co-transduction with humanized [32 microglobulin
increases the expression of human HLA-A2 or chimeric human/non—human HLA—A2/H-2K,
as demonstrated by the shift of curves to the right.
Example 1.2. Engineering a Chimeric HLA—A2/H-2K Locus.
The mouse H-2K gene was humanized in a single step by construction of a
unique targeting vector from human and mouse bacterial artificial some (BAC) DNA
using VELOClGENE® technology (see, e.g., US Pat. No. 6,586,251 and Valenzuela et al.
(2003) High-throughput engineering of the mouse genome coupled with high-resolution
expression analysis. Nat. Biotech. 21(6): 652-659). DNA from mouse BAC clone RP23-
173k21 (lnvitrogen) was modified by homologous recombination to e the genomic
DNA encoding the a1, a2 and a3 domains of the mouse H-2K gene with human genomic
DNA encoding the (11, a2 and a3 subunits of the human HLA-A gene (FlG. 5).
y, the c sequence encoding the mouse the (11, a2 and a3 subunits of
the H-ZK gene is replaced with the human genomic DNA encoding the a1, a2 and a3
domains of the human HLA-A*0201 gene in a single targeting event using a ing vector
comprising a hygromycin cassette flanked by loxP sites with a 5’ mouse homology arm
containing ce 5’ of the mouse H-2K locus including the 5’ untranslated region (UTR;
’ homology arm is set forth in SEQ ID NO: 1) and a 3’ mouse homology arm containing
c sequence 3’ of the mouse H—2K a3 coding sequence (3’ gy arm is set forth
in SEQ lD NO: 2).
The final construct for targeting the endogenous H-2K gene locus from 5’ to 3’
included (1) a 5’ homology arm containing ~200 bp of mouse genomic sequence 5’ of the
endogenous H-2K gene including the 5’UTR, (2) ~1339 bp of human genomic sequence
including the HLA—A*0201 leader sequence, the HLA—A*0201 leader/0L1 intron, the HLA-
A*0201 (x1 exon, the HLA—A*0201 a1—oc2 intron, the HLA-A*0201 a2 exon, ~316 bp of the 5’
end of the a2—d3 intron, (3) a 5’ loxP site, (4) a hygromycin cassette, (5) a 3’ onP site, (6)
~580 bp of human genomic ce including ~304 bp of the 3’ end of the or2-(13 intron,
the HLA-A*0201 (X3 exon, and (7) a 3’ homology arm containing ~200 bp of mouse genomic
sequence including the intron between the mouse H-2K a3 and transmembrane coding
sequences (see FlG. 5 for schematic entation of the H-2K targeting vector). The
sequence of 149 nucleotides at the junction of the mouse/human sequences at the 5’ of the
targeting vector is set forth in SEQ lD NO: 3, and the sequence of 159 nucleotides at the
junction of the human/mouse sequences at the 3’ of the targeting vector is set forth in SEQ
ID NO:4. Homologous recombination with this targeting vector d a modified mouse H-
2K locus containing human genomic DNA encoding the (11, <12 and (13 s of the HLA-
A*0201 gene operably linked to the endogenous mouse H-2K transmembrane and
cytoplasmic domain coding sequences which, upon translation, leads to the formation of a
chimeric human/mouse MHC class l n.
The targeted BAC DNA was used to electroporate mouse F1 H4 ES cells to
create modified ES cells for generating mice that express a chimeric MHC class i protein on
the surface of nucleated cells (6.9., T and B lymphocytes, macrophages, neutrophils). ES
cells containing an insertion of human HLA sequences were identified by a quantitative
TAQMAN TM assay. Specific primer sets and probes were designed for detecting insertion of
human HLA sequences and associated selection cassettes (gain of allele, GOA) and loss of
endogenous mouse sequences (loss of , LOA). Table 1 identifies the names and
locations detected for each of the probes used in the quantitative PCR .
Table 1: Probes Used For Genotyping
Region Detected by
Probe -fi
cm cassette éCGAGCGGGT TCGGCCCATT
Human HLA~A2 (12- AGTCCTTCAG CCTCCACTCA
Human HLA—A2 (12 TACCACCAGT ACGCCTACGA
5112H2 Human “LAN “2' ATCCTGTACC AGAGAGTG I
(x3 intron
The selection cassette may be removed by methods known by the skilled n.
For example, ES cells bearing the chimeric mouse MHC class I locus may be
transfected with a construct that expresses Cre in order to remove the “loxed” ycin
cassette introduced by the insertion of the targeting construct containing human HLA-
A*0201 gene sequences (See . The hygromycin cassette may optionally be removed
by breeding to mice that express Cre recombinase. Optionally, the hygromycin cassette is
ed in the mice.
Targeted ES cells described above were used as donor ES cells and introduced
into an 8-cell stage mouse embryo by the VELOCIMOUSE® method (see, e.g., US Pat. No.
754 and irou et al. (2007) F0 generation mice that are essentially fully d
from the donor argeted ES cells allowing immediate phenotypic analyses Nature
Biotech. 25(1):91-99). VELOCIMICE® (F0 mice fully derived from the donor ES cell)
independently bearing a chimeric MHC class l gene were identified by genotyping using a
modification of allele assay (Valenzuela et al., supra) that detects the presence of the unique
human HLA-A*0201 gene sequences.
Example 1.3. In Vivo Expression of Chimeric HLA—A/H-2K in Genetically Modified Mice.
A heterozygous mouse carrying a genetically modified H-ZK locus as described
in Example 1.2 was analyzed for expression of the chimeric HLA-A/H—ZK protein in the cells
of the animal.
WO 63346
Blood was obtained separately from a wild-type and a HLA—A/H—2K chimeric
heterozygote (A2/H2K) mouse. Cells were stained for human HLA-A2 with a rythrin—
conjugated (PE) anti—HLA~A antibody, and exposed to an allophycocyanin-conjugated anti-
H-2Kb antibody for one hour at 4°C. Cells were analyzed for expression by flow cytometry
using antibodies specific for HLA-A and H-2K". FlG. 6A shows the expression of H-2Kb and
HLA—A2 in the wild—type and chimeric heterozygote, with chimeric heterozygote sing
both proteins. FIG. BB shows expression of both the H-2Kb and the chimeric HLA—A2/H2K in
the heterozygous mouse.
Example 2: Construction and Characterization of Genetically Modified [32
Microglobulin Mice
Example 2.1: Engineering a Humanized fi2 Microglobulin Locus
The mouse [32 microglobulin ({32m) gene was humanized in a single step by
construction of a unique ing vector from human and mouse bacterial artificial
some (BAC) DNA using VELOCIGENE® technology (see, e.g., US Pat. No.
6,586,251 and Valenzuela et al., supra).
y, a targeting vector was generated by bacterial homologous recombination
containing mouse [32m upstream and downstream homology arms from BAC clone 89C24
from the RPCl-23 library (lnvitrogen). The mouse homology arms were engineered to flank
a 2.8 kb human [32m DNA fragment extending from exon 2 to about 267 nucleotides
downstream of ding exon 4 (FlG. 7). A drug selection cassette (neomycin) flanked by
recombinase recognition sites (e.g., onP sites) was engineered into the targeting vector to
allow for subsequent selection. The final ing vector was linearized and electroporated
into a F1H4 mouse ES cell line (Valenzuela et al., .
ed ES cell clones with drug cassette removed (by introduction of Cre
recombinase) were introduced into an 8—cell stage mouse embryo by the MOUSE®
method (see, e.g., US Pat. No. 7,294,754 and Poueymirou et al., supra). VELOClMlCE®
(F0 mice fully derived from the donor ES cell) g the humanized [52m gene were
identified by screening for loss of mouse allele and gain of human allele using a modification
of allele assay (Valenzuela et al., supra).
Example 2.2: Characterization of Humanized fi2 Microglobulin Mice
Mice heterozygous for a humanized [32 microglobulin (62m) gene were evaluated
for expression using flow cytometry (Fle 8. and 9).
] Briefly, blood was isolated from groups (n=4 per group) of wild type, humanized
02m, humanized MHC (i.e., human HLA) class i, and double humanized [32m and MHC
class l mice using techniques known in art. The blood from each of the mice in each group
was treated with ACK lysis buffer (Lonza Walkersville) to eliminate red blood cells.
Remaining cells were stained using fluorochrome conjugated anti-CD3 (17A2), anti-CD19
(1 D3), anti-CD11b (M1/70), anti-human HLA class I, and anti-human {32 microglobulin (2M2)
antibodies. Flow cytometry was performed using BD-FACSCANTOT“ (BD Biosciences).
Expression of human HLA class l was detected on cells from single humanized
and double zed animals, while expression of {32 microglobulin was only detected on
cells from double humanized mice (. ression of human [32m and human HLA
class i resulted in an increase of detectable amount of human HLA class l on the cell surface
ed to human HLA class l expression in the absence of human [32m (FlG.9; mean
fluorescent intensity of 2370 versus 1387).
e 3. immune Response to Flu an Epstein-Barr Virus (EBV) Peptides Presented
by APCs from Genetically Modified Mice Expressing HLA-A2/H-2K and Humanized £52
lobulin.
PBMCs from several human donors were ed for both HLA-A2 expression
and their ability to mount a response to flu and EBV peptides. A single donor was selected
for subsequent ments.
Human T cells are isolated from PBMCs of the selected donor using negative
selection. Splenic non-T cells were isolated from a mouse heterozygous for a chimeric HLA—
A2/H-2K and heterozygous for a zed fiZ-microglobulin gene, and a wild—type mouse.
About 50,000 splenic non-T cells from the mice were added to an Elispot plate coated with
anti-human lFNy dy. Flu peptide (10 micromolar) or a pool of EBV peptides (5
micromolar each) was added. Poly lC was added at 25 micrograms/well, and the wells were
incubated for three hours at 37°C at 5% C02. Human T cells (50,000) and anti-human CD28
were added to the splenic non T cells and the peptides, and the wells were incubated for 40
hours at 37°C at 5% C02, after which an lFNy Elispot assay was performed.
As shown in , human T cells were able to mount a response to flu and
EBV peptides when presented by mouse APCs that expressed the chimeric HLA-A2/H-2K
and zed [32 microglobulin on their surface.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than
routine experimentation, many equivalents of the specific ments of the invention
described herein. Such equivalents are intended to be encompassed by the following
claims.
Entire contents of all non-patent documents, patent applications and patents cited
throughout this application are incorporated by reference herein in their entirety.
Where the terms “comprise”, “comprises”, “comprised” or “comprising” are used in
this specification (including the ) they are to be interpreted as specifying the presence
of the stated es, integers, steps or components, but not precluding the presence of one
or more other features, rs, steps or components, or group thereof.
] The discussion of documents, acts, materials, devices, articles and the like is
included in this specification solely for the purpose of providing a context for the present
invention. It is not ted or represented that any or all of these matters formed part of
the prior art base or were common general knowledge in the field relevant to the present
invention as it existed before the priority date of each claim of this application.
Claims (36)
1. A non-human animal comprising at an endogenous Major Histocompatibility Complex I (MHC I) locus a nucleotide sequence encoding a chimeric human/non-human MHC I 5 polypeptide, wherein a human portion of the chimeric polypeptide comprises α1, α2, and α3 domains of a human MHC I polypeptide, and wherein the non-human animal expresses the chimeric non-human MHC I polypeptide. 10
2. The non-human animal of claim 1, wherein the animal is a rodent, wherein the rodent comprises at an endogenous Major Histocompatibility Complex I (MHC I) locus a nucleotide sequence encoding a chimeric human/rodent MHC I polypeptide, wherein a human n of the chimeric polypeptide comprises α1, α2, and α3 domains of a human MHC I ptide, and 15 wherein the rodent expresses the chimeric human/rodent MHC I polypeptide.
3. The rodent of claim 2, wherein the rodent does not express α1, α2, and α3 s of an endogenous rodent MHC I polypeptide from an endogenous rodent MHC I locus.
4. The rodent of claim 2, wherein the nucleotide sequence is operably linked to endogenous rodent tory elements. 20
5. The rodent of claim 2, wherein the rodent is a mouse.
6. The mouse of claim 5, wherein the endogenous locus is a mouse H-2K locus.
7. The rodent of claim 2, wherein a rodent n of the chimeric polypeptide comprises transmembrane and cytoplasmic domains of an endogenous rodent MHC I polypeptide.
8. The rodent of claim 7, wherein the rodent is a mouse, the endogenous rodent MHC I 25 locus is an H-2K locus, and the endogenous rodent MHC I polypeptide is H-2K.
9. The rodent of claim 2, wherein the human MHC I ptide is selected from the group consisting of HLA-A, HLA-B, and HLA-C.
10. The mouse of claim 5 sing at an nous H-2K locus a nucleotide sequence encoding a chimeric human/mouse MHC I polypeptide, 30 wherein a human portion of the chimeric polypeptide comprises α1, α2, and α3 domains of a human HLA-A2 polypeptide and a mouse portion comprises transmembrane and cytoplasmic domains of a mouse H-2K polypeptide, and n the mouse expresses the chimeric /H-2K polypeptide.
11. The mouse of claim 10, n the mouse does not express α1, α2, and α3 domains of the mouse H-2K polypeptide from an endogenous H-2K locus.
12. The rodent of claim 2 or the mouse of claim 10, wherein the human portion of the chimeric polypeptide comprises a human leader sequence. 5
13. The mouse of claim 10, wherein the nucleotide sequence is operably liked to endogenous mouse regulatory elements.
14. The mouse of claim 10, wherein the human HLA-A2 ptide is an HLA-A2.1 polypeptide.
15. The mouse of claim 11, wherein the mouse H-2K locus is an H-2Kb locus. 10
16. A method of ing an MHC I locus of a mouse to express a chimeric human/mouse MHC I polypeptide, wherein the method comprises replacing at the endogenous MHC I locus a nucleotide sequence encoding α1, α2, and α3 domains of a mouse MHC I polypeptide with a nucleotide sequence encoding α1, α2, and α3 s of a human MHC I polypeptide. 15
17. The method of claim 16, wherein the mouse does not express the α1, α2, and α3 domains of the mouse MHC I polypeptide from an endogenous mouse MHC I locus.
18. The method of claim 17, wherein the mouse MHC I locus is an H-2K locus, and the mouse MHC I polypeptide is an H-2K polypeptide.
19. The rodent of claim 9 or the method of claim 17, wherein the human MHC I 20 polypeptide is an HLA-A polypeptide.
20. The method of claim 17, wherein the mouse expresses transmembrane and cytoplasmic domains of the mouse MHC I polypeptide.
21. A non-human animal, rodent or mouse ing to any one of claims 1-15 further comprising at an endogenous non-human 2 microglobulin locus a nucleotide sequence 25 encoding a polypeptide comprising a human 2 microglobulin amino acid sequence, wherein the man animal expresses a human or humanized 2 microglobulin polypeptide.
22. The non-human animal of claim 21, wherein the animal is a rodent, wherein the rodent comprises at an endogenous rodent 2 microglobulin locus a nucleotide sequence encoding a polypeptide comprising a human 2 lobulin amino acid ce, and wherein the 30 rodent ses a human or humanized 2 microglobulin polypeptide.
23. The rodent of claim 22, wherein the rodent does not s a functional endogenous rodent 2 microglobulin polypeptide from an endogenous rodent 2 microglobulin locus.
24. The rodent of claim 22, wherein the tide sequence is operably linked to endogenous rodent 2 microglobulin regulatory elements.
25. The rodent of claim 22, wherein the nucleotide sequence comprises a nucleotide ce set forth in exon 2 to exon 4 of a human 2 microglobulin gene. 5
26. The rodent of claim 22, wherein the nucleotide sequence comprises nucleotide sequences set forth in exons 2, 3, and 4 of a human 2 microglobulin gene.
27. The rodent of claim 26, wherein the nucleotide sequence further comprises a tide sequence set forth in exon 1 of a rodent 2 microglobulin gene.
28. The rodent of any one of claims 22-27, wherein the rodent is a mouse. 10
29. The method of any one of claims 16-20, further sing modifying a 2 microglobulin locus of a mouse to express a human or humanized 2 lobulin polypeptide, wherein the method comprises replacing at the endogenous mouse 2 microglobulin locus a nucleotide sequence encoding a mouse 2 microglobulin polypeptide with a nucleotide sequence ng a human or humanized 2 microglobulin polypeptide. 15
30. The method of claim 29, wherein the mouse does not s a functional mouse 2 microglobulin polypeptide from an endogenous 2 microglobulin locus.
31. The method of claim 29, wherein the tide sequence encoding the human or humanized 2 microglobulin polypeptide comprises a nucleotide sequence set forth in exon 2 to exon 4 of a human 2 microglobulin gene. 20
32. The method of claim 29, wherein the nucleotide sequence encoding the human or humanized 2 microglobulin polypeptide comprises nucleotide sequences set forth in exons 2, 3, and 4 of a human 2 microglobulin gene.
33. The method of claim 29, wherein the modified locus retains a nucleotide sequence of exon 1 of a mouse 2 microglobulin gene. 25
34. The method of any one of claims 16–20 or 29, wherein the replacement is made in a single ES cell, and the single ES cell is introduced into a mouse embryo to make a mouse.
35. The mouse of claim 28, wherein the expression of the human or humanized 2 microglobulin polypeptide increases the expression of the chimeric human/mouse MHC I polypeptide as compared to the expression of the ic human/mouse MHC I polypeptide 30 in the absence of expression of human or humanized 2 lobulin polypeptide.
36. The non-human animal ing to claim 1, or the method according to claim 16, substantially as hereinbefore described with reference to the Examples and/or
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ719373A NZ719373B2 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552582P | 2011-10-28 | 2011-10-28 | |
US201161552587P | 2011-10-28 | 2011-10-28 | |
US61/552,587 | 2011-10-28 | ||
US61/552,582 | 2011-10-28 | ||
US201261700908P | 2012-09-14 | 2012-09-14 | |
US61/700,908 | 2012-09-14 | ||
PCT/US2012/062042 WO2013063346A1 (en) | 2011-10-28 | 2012-10-26 | Genetically modified major histocompatibility complex mice |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623456A NZ623456A (en) | 2016-05-27 |
NZ623456B2 true NZ623456B2 (en) | 2016-08-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017279797B2 (en) | Genetically modified major histocompatibility complex mice | |
US20200375159A1 (en) | Genetically modified major histocompatibility complex animals | |
AU2012324016B8 (en) | Genetically modified major histocompatibility complex mice | |
AU2020204410B2 (en) | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules | |
NZ623456B2 (en) | Genetically modified major histocompatibility complex mice | |
NZ719373B2 (en) | Genetically modified major histocompatibility complex mice |